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Abstract
We introduce an in vitro diagnostic magnetic biosensing platform for immunoassay and nucleic acid
detection. The platform has key characteristics for a point-of-use (POU) diagnostic: portability,
low-power consumption, low cost, and multiplexing capability. As a demonstration of capabilities,
we use this platform for the room temperature, amplification-free detection of a 31 bp DNA oligomer
and interferon-γ (a protein relevant for tuberculosis diagnosis). Reliable assay measurements down
to 100 pM for the DNA and 1 pM for the protein are demonstrated. We introduce a novel “magnetic
freezing” technique for baseline measurement elimination and to enable spatial multiplexing. We
have created a general protocol for adapting integrated circuit (IC) sensors to any of hundreds of
commercially available immunoassay kits and custom designed DNA sequences.
We also introduce a method for immunotherapy treatment of malignant gliomas. We utilize
leukocytes internalized with immunostimulatory nanoparticle-oligonucleotide conjugates to localize
and retain immune cells near the tumor site. As a proof-of-principle, we develop a novel cell imag-
ing and incubation chamber for in vitro magnetic motility experiments. We use the apparatus to
demonstrate the controlled movement of magnetically loaded THP-1 leukocytes.
Finally, we introduce an IC transmitter and power amplifier (PA) that utilizes electronic digital
infrastructure, sensors, and actuators to self-heal and adapt to process, dynamic, and environmental
variation. Traditional IC design has achieved incredible degrees of reliability by ensuring that billions
of transistors on a single IC die are all simultaneously functional. Reliability becomes increasingly
difficult as the size of a transistor shrinks. Self-healing can mitigate these variations.
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1Chapter 1
Introduction
Sensing and actuation are the interfaces of intelligent systems: they allow a functional system to
adapt to its environment. Being able to monitor one’s health and treat disease is the cornerstone
of health care. Mankind’s development of diagnostic tools and therapeutics has extended our lives
and improved our well-being. In this dissertation, we discuss biosensing and magnetic actuation.
We first introduce the landscape of an important segment of health care diagnostics—in vitro
diagnostics (IVD). We discuss the transition from central lab analyzers to patient-operated devices.
A brief introduction of representative commercial devices is presented along with their core tech-
nologies. Next, we consider magnetic trafficking as a therapeutic for brain tumor treatment. We
discuss the various types of brain tumors and the lack of effective treatment for them. We introduce
the promising prospect of immunotherapy and how magnetic actuation can be of particular utility.
1.1 Point-of-use Diagnostics
IVD is a booming industry with an estimated global market capitalization of over $50 billion annually
[1]. IVD is a rapidly growing industry due to the ability to detect early onset of disease and begin
early treatment. Early treatment of disease usually increases probability of successful treatment
and lowers treatment costs. The detection of a disease is primarily useful when the detection event
affects a clinical decision.
1.1.1 Immunochemistry
Immunochemistry is the largest market within the IVD industry with a compound annual growth rate
of 7% between 2012 and 2014 [1]. The market consists primarily of large automated immunoassay
and clinical chemistry analyzers used in developed countries. Clinical chemistry analyzers are large,
high-throughput, automated measurement systems capable of detection of a subset of hundreds of
potential biomarkers in human bodily fluid. Some examples of these systems are the Beckman
2Figure 1.1: Global in vitro diagnostics (IVD) market in 2012 [1]. The IVD market is estimated to
exceed $50 billion annually.
Coulter Unicel DxC 880i (Fig. 1.2), Roche Cobas Integra 6000, and Ortho VITROS 5600. These
systems have a variety of instrumentation for full automation such as:
• Heater
• Refrigerator
• Fluid Mixing
• Waste Disposal
• Magnetic Separation
• Optical Analyzer
• Power Supply
• Reagents
• Fluid Handling
• Reaction Vessel
• Sample Vessel
• Consumables
Although these systems have extremely high throughput, they are expensive and require constant
power, technician support, and a sterile lab facility to operate. Although this has been a boon
for high volume tests in developed countries, it does not have the capability to operate in resource
limited settings. Furthermore, it is difficult to transport, cannot be operated near the point of care,
and is not suitable for infrequent testing.
3Many analyzers rely on immunoassays for analyte detection. An analyte is a biomarker for a
disease (for example, a protein, molecule, or even an antibody (used in serological tests)). Im-
munoassays were first developed in the 1950s and their use was popularized in the 1970s. They
detect analytes through the labeling of antigens by antibodies. The popularity of immunoassays is
largely attributable to the relative ease of developing antibodies for a particular antigen.
To develop an antibody (also known as immunoglobulin) for an antigen, a host mammal (usually
a mouse, rabbit, goat, or sheep) is immunized against the antigen through antigen injection. The
host’s immune system will naturally develop specific antibodies against the antigen. Next, the
spleen is removed from the host and disassociated in a culture medium. The B cells from the
disassociated spleen are then isolated and cultured. Myeloma cells are introduced and fused to
B cells using polyethylene glycol (PEG) to form hybridomas. The resulting culture can be used to
produce polyclonal antibodies or separated to form monoclonal antibodies. Polyclonal antibodies are
heterogeneous and bind to potentially overlapping epitopes. Monoclonal antibodies have a specific
Fab region that binds to a specific antigen epitope.
Figure 1.2: Beckman Coulter Unicel DxC 880i. This large immunoanalyzer is a fully automated
system requiring constant power, lab infrastructure, and technician support.
There are two types of immunoassays: competitive and non-competitive. In competitive im-
munoassays (simpler than a non-competitive immunoassay), two antigens compete to bind to an
antibody. Binding to the target analyte is energetically favorable to binding to the non-target anti-
gen. The non-target antigen is usually labeled. The amount of signal present from the labeled,
bound antigen, or labeled, unbound antigen can be anti-correlated to the concentration of target
analyte in solution. In a non-competitive immunoassay, a single target analyte is bound to a single
(one-site) or pair (two-site) of antibodies. In a one-site noncompetitive immunoassay, a labeled
antibody is bound to an analyte. Unbound antibodies are separated or washed away and the signal
from the remaining antibodies are measured and correlated to analyte concentration. In a two-site
noncompetitive immunoassay, such as a sandwich enzyme-linked immunosorbent assay (ELISA), a
4capture antibody binds an analyte to a substrate and a probe antibody labels the analyte. The
amount of signal present from the probe antibody is correlated to the presence of target analyte.
An immunoassay can also be categorized as a heterogeneous or homogeneous. In a heterogeneous
assay, analytes are captured onto a substrate and bound to a labeled antibody. Unbound labels are
washed or separated from the analyte. In a homogeneous assay, bound and unbound analytes are
differentiated by some mechanism and does not require separation of analyte from label. Binding to
a substrate is also not required. This simplifies sample preparation and handling.
Magnetic particles are desirable for IVD as a binding substrate because no centrifugation is
needed and no clotting occurs, and they can be simultaneously used for washing and elution, they
are inexpensive, they can be easily concentrated, and they can be used for higher IVD throughput.
1.1.2 Molecular Diagnostics
Molecular diagnostics is one of the fastest growing markets in the IVD industry with a compound
annual growth rate of 11% between 2012 and 2014 [1]. It consists of genome and proteome anal-
ysis of humans and disease for clinical decisions. It consists of four categories: pathogenomics,
pharmacogenomics, genetic testing, and blood donor screening.
1.1.2.1 Pathogenomics
Pathogenomics extends beyond pathogen infections. Metagenomic analysis of microbe diversity
elucidates our understanding of complex interdependencies of disease and microbes. The human
intestinal microbiota, for example, is composed of between 1013 to 1014 microorganisms with at
least 100 times as many genes as the human genome [6]. These microorganisms have been linked to
topics such as obesity [7], immunity [8], and cancer [9].
1.1.2.2 Pharmacogenomics
The human population shares 99.9% of its DNA sequence. The remaining 0.1% of variations account
for virtually all our phenotypical differences. Approximately 80% of our genetic differences are due
to single nucleotide polymorphisms (SNP). Other variations consist of sequence repeat, deletion, and
chromosomal rearrangement. Our genetic variations can affect our drug metabolism. This becomes
important when deciding the proper dosage levels of pharmaceutical drugs in treating disease.
One example of pharmacogenomics is the assessment of drug metabolism of the enzyme family
Cytochrome P450. P450s are believed to be involved in approximately 75% of drug metabolism [10].
One of the members of the family, Cytochrome P450 2C9 (CYP2C9), is encoded by CYP2C9 gene.
Over 50 SNP are located on the CYP2C9 gene, and thus, it is highly polymorphic [11]. CYP2C9
activity is responsible for the determination in warfarin dosing, an anticoagulant used to treat
5thrombosis (blood clotting) [12]. However, dosing must be determined on a case-by-case basis and
can vary by 20X [12]. An insufficient dose leads to illness while an excessive dose leads to severe
bleeding. Nanosphere’s commercial Verigene system assesses two alleles of the CYP2C9 gene to
determine proper warfarin dosing [13].
1.1.2.3 Genetic Testing
Human genetic analysis is vital in the fields of forensics, paternity testing, inherited diseases, disease
predisposition, and family planning.
1.1.2.4 Blood Donor Screening
High throughput screening for blood donations is essential for protecting the recipient from blood-
borne pathogens. Donated blood is usually first screened using a high sensitivity, low specificity
diagnostic. Next, false positives are eliminated using a higher specificity diagnostic. The WHO
recommends a country have bare minimum screening for HIV-1 and HIV-2 using a combination
of HIV antigen-antibody or HIV antibodies, hepatitis B using surface antigen HBsAg, Hepatitis C
using HCV antigen-antibody or HCV antibodies, and syphillis using treponemal antibodies [14].
However, it estimates 47% of donations in low-income countries are tested in laboratories without
quality assurance [15].
1.1.3 Point-of-Care Diagnostics
Point-of-care (POC) diagnostics is testing performed at or near the site where clinical care is deliv-
ered [16]. The last decade has seen substantial growth in POC diagnostics [1,17]. The development
of POC devices reduces initial capital costs, resource and infrastructure constraints, diagnosis and
treatment time delay, and inflexibility associated with central lab analyzers [18, 19]. Several POC
diagnostic systems have been recently developed using various detection methods such as electro-
chemical, magnetic, mechanical, optical, or electronic detection methods. A brief review of a few
recent POC diagnostic systems is provided.
Nanosphere’s Verigene system [13] (Fig. 1.3) is a technology based upon Professor Mirkin’s bio-
barcode assay [20]. The assay uses magnetic labels coated with capture antibodies or nucleic acids
for a target DNA or protein. Gold nanoparticles are functionalized with a separate capture antibody
or oligonucleotide, and an encoding oligonucleotide. After magnetic separation, the oligonucleotides
are released and optically scanned or imaged using scattered light from evanescent excitation. Signal
amplification occurs from nanoparticle catalyzed silver reduction. The detection system is able to
detect infections (including respiratory, gastrointestinal, and bloodstream) as well as perform cardiac
tests [13].
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Figure 1.3: Nanosphere’s Vergene diagnostic system. (a) Verigene Reader and (b) disposable detec-
tion cartridge.
Cepheid Inc.’s GeneXpert system [21] (Fig. 1.4) utilizes amplification and integrated sample
preparation for the multiplexed detection of various infectious diseases. The system uses a miniatur-
ized sonicator for mechanical cell lysis [22]. Amplification is achieved using PCR. Detection consists
of real-time fluorescence detection. The company is able to achieve lower costs by a lack of commit-
ment to lateral flow patents. Integrated sample preparation remains their largest hurdle. Cepheid’s
debut was after the 2001 anthrax attacks where the system was purchased by several US federal
agencies for anthrax detection. Since then, the system has been backed by the World Health Orga-
nization (WHO) for tackling HIV in Africa as well as the Bill & Melinda Gates Foundation. The
GeneXpert system costs approximately $30,000 (depending on capabilities) and the test cartridge
costs approximately $25 unsubsidized.
The Xpert MTB/RIF assay has the potential to revolutionize tuberculosis (TB) diagnostics. In
2013, a total of 9 million people contracted TB and 1.5 million died from the disease, making it the
world’s second greatest infectious agent killer (after HIV) [23]. Drug resistant TB remains a large
global problem. A 90bp mutation region in TB determines its resistance to refampin. A combination
of 5 molecular beacons could determine a strain’s resistance to refampin and optimize treatment.
However, challenges remain as the system requires uninterrupted power and a lab to operate.
GenMark Dx’s (formerly Osmetech) eSensor XT-8 is a gold electrode PCB based diagnostic (Fig.
1.6) [2]. The system uses polymerase chain reaction (PCR) amplification to improve sensitivity. The
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Figure 1.4: Cepheid’s GeneXpert diagnostic system. (a) Automated instrument and (b) disposable
detection cartridge.
sample preparation is shown in Fig. 1.7a. Current capabilities enable a multiplexibility of 72. The
disposable cartridge combines the PCB sensor with microfluidics. Detection is based off of an
amperometric measurement of ferrocene. The sensing technology is shown in Fig. 1.7b.
8Figure 1.5: Diagnostic Devices Landscape. Diagnostic devices can be broadly classified under three
categories: central lab analyzers, Point-Of-Care, and Point-Of-Use.
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Figure 1.6: GenMark’s eSensor XT-8 diagnostic system. (a) Detection instrument and (b) detection
cartridge [2].
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(b)
Figure 1.7: GenMark’s eSensor XT-8 (a) sample preparation and (b) detection technology [2].
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1.1.4 Self-monitoring Blood Glucose and the Point-of-Use Diagnostic
As traditional central lab testing has evolved into POC diagnostics, the prevalence of point-of-use
(POU) diagnostics has increased. A POU diagnostic can be performed by the end patient and some
or all of the clinical care is administered by the end patient. Perhaps the best example of a POU
diagnostic is the handheld blood glucose monitor.
A blood glucose monitor is used to manage Type 1 and Type 2 diabetes mellitus (DM). Diabetics
require a regimen of insulin injections to help manage blood sugar levels. The monitor helps to
evaluate the effectiveness of previous insulin injections and to determine the dosage next injection.
Although proper treatment also requires a doctor’s evaluation of the patient’s cardiovascular system,
the monitor combined with self-administered insulin injection enables the patient more flexibility
and more effective treatment at substantially lower treatment costs.
Therefore, POU diagnostics has a distinct advantage in treating patients in limited resource
settings, decreasing the time between diagnosis to treatment, and empowering the patient through
increased flexibility. POU diagnostics are particularly useful in diagnosing diseases where early
detection is critical to successful treatment. Some examples of favorable disease candidates for POU
diagnostics include sepsis, pertussis (whooping cough), malaria, tuberculosis (TB), influenza, and
human immunodeficiency virus (HIV).
1.1.5 A POU Diagnostic for Protein and Nucleic Acid Detection
We propose a POU diagnostic platform compatible with two of the largest IVD markets: molecular
diagnostics and immunochemistry. This detection system is based on the frequency-shift biosen-
sor [24–26]. Frequency-shift based magnetic sensing is a measurement technique utilizing a comple-
mentary metal-oxide-semiconductor (CMOS) integrated-circuit (IC) chip for magnetic label detec-
tion. The sensing scheme leverages the low-cost manufacturing for IC chips while demonstrating
potential for multiplexing capabilities. In this article, we present modifications to this scheme
for POC viability. We introduce a handheld reusable reader and a disposable open-well cartridge
for the detection of nucleic acids and antigens. The diagnostic system utilizes a novel “magnetic
freezing” technique to reduce measurement time, obviate baseline measurement before or during
biological assay, and reduce sensor noise. We utilize these enhancements for the room temperature,
amplification-free detection of a 31 base-pair DNA oligomer and the interferon-γ (IFN- γ) protein.
We have demonstrated reliable measurements down to 100 pM for the DNA assay and 1 pM for the
protein.
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1.2 Magnetic Particle Trafficking for Brain Tumor Therapy
1.2.1 Brain and Central Nervous System Tumors
The human brain is composed of glial cells, blood vessels, and neurons. Gliomas are tumor cells de-
rived from glial cells in the brain or spine. Gliomas account for 30% of all brain and central nervous
system (CNS) tumors but 80% of malignant brain tumors [27]. Approximately 20% of gliomas are
benign; the remaining are malignant [3]. Malignant gliomas are the most common and fatal primary
brain neoplasm [28, 29] with median survival times between 1-2 years [3]. Gliomas are divided into
three categories: ependymomas, astrocytomas, and oligodendrogliomas. Ependymomas make up
2-3% of gliomas and tend to occur intracranially in children. Astrocytomas make up approximately
half of all brain tumors and are divided into grades (by the WHO) of increasing severity: I (pi-
locytic astrocytoma, pleomorphic xanthoastrocytoma, subependymal giant cell astrocytoma, and
subependymoma), II (low-grade astrocytoma and mixed oligoastrocytoma), III (anaplastic astrocy-
toma), and IV (glioblastoma multiforme). Oligodedrogliomas are divided into two grades: II (low
grade) and III (high grade analplastic).
Figure 1.8: One-, two-, three-, four-, five-, and ten-year relative survival ratesa,b for selected malig-
nant brain and central nervous system tumors, SEER 17 registries, 1995-2008c [3]. Glioblastomas
are the most common type of brain and CNS tumor with median survival time less than one year.
13
1.2.2 Malignant Glioma Treatment Options
The three most common treatment options for malignant gliomas are chemotherapy, surgery, and
radiation therapy. Chemotherapy is the use of one or several chemical substances used to treat
gliomas. However, chemotherapeutic agents are usually cytotoxic. During treatment, less than 1%
of the chemotherapeutic agent is delivered to the tumor cells. In brain and CNS tumors, this fraction
is further reduced by the blood-brain barrier [30]. This results in healthy tissue receiving toxic sub-
stances and damage. Common side-effects of chemotherapy include alopecia (hair loss), mucositis
(digestive tract inflamation), myelosuppression (suppressed blood production), and immunosuppres-
sion (suppressed immune function). On the other hand, surgery is a difficult treatment option for
deeply embedded tumors and sacrifices essential peripheral healthy tissue. Finally, radiation therapy
can damage essential healthy tissue and have many undesirable side effects.
Figure 1.9: Various types of leukocytes [4]. Leukocytes can be classified by innate or adaptive
immunity.
A promising new class of cancer treatment is immunotherapy [31]. One subset of immunotherapy
is activated immune response, whereby the patient’s leukocytes (white blood cells) are stimulated
to elicit a response to the tumor (Fig. 1.9). After the activated response, the likelihood of immuno-
logical memory of the tumor is increased (retained immunity). Stimulated immunotherapy uses the
body’s own immune system to trigger its ability to seek out and kill cancer. Our collaborators have
shown that carbon nanotubes conjugated with CpG oligodeoxynucleotides resulted in the stimula-
tion of toll-like receptor-9 (TLR9) and cured 50-60% of mice with established gliomas [29]. This
nanotube-CpG construct is readily taken up by macrophages, microglia, NK cells, and dendritic
cells [29].
Activation of TLRs enhances the uptake of microorganisms by phagocytic cells, promotes se-
cretion of Th1 cytokines, and mediates leukocyte recruitment to infected tissues. Generally, TLR9
is not found on the cell surface, but is initially located in the endoplasmic reticulum (ER) and is
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then found colocalized with CpGs in the lysosomes following stimulation [32]. Therefore, because
CpG-induced immune stimulation is dependent upon TLR9 interacting with CpG inside the endoso-
mal compartment, using a platform that achieves endosomal delivery of CpG may be an attractive
strategy for enhancing CpG efficacy [33].
When the cured mice were reintroduced to intracranial tumors, full immunity was retained.
Furthermore, they have shown that uptake of CpG coated nanoparticles (NP) in tumor associated
macrophages improves NP delivery and immune memory [34]. Various nanoparticles have been
investigated as potential candidates for the delivery of CpGs, including liposomes [35], self-assembling
DNA nanoparticles [36], poly(lactic-co-glycolic acid) nanoparticles [37], and gold nanoparticles [38].
CpG induces an immune response because it is a single-stranded DNA. Naturally occurring single-
stranded DNA is indicative of a bacterial or viral infection and therefore elicits an inflammatory
immune response. NP CpG is believed to be more effective than free CpG because the NP acts as
an “anchor” for the CpG and increases its retention time near the tumor site.
1.2.3 Magnetically Trafficking Macrophages for Guided Immunotherapy
Because increased retention time of CpG near the glioma site appears to be beneficial for im-
munotherapy [34], this effect could potentially be enhanced using magnetic force. Instead of non-
magnetic NPs, iron-oxide NPs could act as a new magnetically guidable substrate for the CpG.
We hypothesize that using super paramagnetic iron oxide nanoparticles (SPIONs) as the delivery
platform for the CpG would enable magnetic control of immune cells that endocytosed the particles.
SPIONs respond to magnetic fields and allow for the controlled delivery of conjugated chemother-
apeutics [39]. This technique may even allow for targeted delivery deep within the body [40, 41].
Magnetic targeting of drug delivery has been applied to brain tumors [42]. Recently, magnetic
targeting has been extended to cells by labeling desired cell populations with SPIONs and other
magnetic particles. One focus of this work has been attracting loaded cells to magnetized implanted
devices, such as stents [43,44]. Another primary application has been targeting loaded stem cells for
regenerative medicine [45–48]. A limited number of publications have also described magnetic con-
trol of loaded immune cells [49]. Clinically, we envision that a SPION-based immunotherapy could
be injected intracranially, internalized by local immune cells, and then enable the magnetically-
controlled migration of these activated immune cells for the treatment of multifocal disease or deep
brain tumors. Given a system that can adjust the field in the brain volume, particles could be aggre-
gated and retained near the tumor site. Leukocytes such as macrophages would become activated
after endocytosis of the CpG NPs. After endocytosis, the macrophages would become aggregated
and retained near the tumor site, increasing their effectiveness in treating the tumor. Additionally,
the field could be temporally adjusted as the neoplasm spreads or shrinks in size. Another benefit
of magnetic particles is that they can be used as a magnetic resonance imaging contrast for in vivo
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evaluation of macrophage distribution. A few possible treatment scenarios could be attempted:
• Macrophages would first be extracted from the patient. The macrophages would be introduced
to a CpG NP media solution. After endocytosis, the macrophages would be reintroduced to
the patient. A magnetic field profile would guide the macrophages to the tumor site.
• Macrophages would similarly be extracted from the patient. After introduction and endocy-
tosis of CpG NPs, the macrophages would be injected directly to the tumor site. A magnetic
field profile would retain the activated macrophages near the tumor site.
• Instead of macrophage extraction, CpG NPs could be directly injected to the tumor site. A
magnetic field profile would retain particles near the tumor site while the body’s immune
system recruits leukocytes to the NPs.
1.2.4 Prototyping a Wearable, Dynamically Programmable Magnetic Field
(DPMF) Head Enclosure
The eventual treatment will require precise 3D magnetic control of magnetic field profiles within
the brain. This could consist of a collection of programmable current elements enclosing a portion
of the head. By choosing the magnitude and direction of a collection of current elements, a wide
variety of magnetic fields can be achieved. However, monitoring the effectiveness of guided cell
motility in the brain is difficult. Magnetic resonance imaging (MRI) would first require removal of
the programmable current elements. It is difficult to image to high resolutions on a short timescale
using MRI, but longer timescales would be prohibitively expensive to operate (despite recent im-
provements from compressed sensing). 3D slice fluorescence imaging of a brain is more suitable for
an endpoint evaluation and does not allow for time-lapsed imaging. Radioactive isotope imaging
would also require complicated infrastructure. To evaluate both short-term and long-term motility
of nanoparticles and cells, we designed a novel imaging, incubation, and magnetic manipulation cell
box (Fig. 1.10a). The cell box allows for long-term viability of cells while adapting to a standard 100
mm petri dish. A large cell media reservoir provides nutrients to cells while an internal atmosphere
distribution system ensures pH control of the media. The cell box and petri dish are compact enough
to be imaged with typical inverted microscopes. A clear glass coverslip separating the DPMF and
cell media allows for easy visual alignment. A waterproof seal separates electronics from cell media.
A custom DPMF controller (Fig. 1.10b) enables the DPMF to interface to a computer for accurate
timing of magnetic profile actuation.
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(a)
(b)
Figure 1.10: (a) One of the core components of the DPMF device is a 3D-printed cell box. The box
is printed from ABS plastic and contains life-support features for magnetically trafficked cells. A
CO2 inlet port and distribution channels ensure optimal pH of cell media. A coverslip slot allows
for the waterproof attachment of a large coverslip. The interface ensures that the system electronics
do not interfere with cell media. The cell box adapts to a standard 100 mm petri dish and fits on
typical inverted microscopes. (b) A computer-interfaced controller adjusts the current distribution
of the DPMF. The total size of the controller is 100 mm x 200 mm.
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1.3 Contributions
In this dissertation, we present an IC-based platform for biological sensing. We also propose a
method for magnetically-guided immunotherapy of intracranial gliomas. We introduce an imaging,
incubation, and magnetic manipulation chamber for in vitro cell trafficking. We also use princi-
ples of self-healing IC design in a mm-wave transmitter architecture and a high-power stacked PA.
Specifically, we demonstrate:
• A handheld, reusable reader and low-cost disposable cartridge for the detection of nucleic acids
and antigens.
• A novel magnetic freezing technique for baseline measurement elimination and to enable spatial
multiplexing.
• Room temperature, amplification-free detection of a 31 bp DNA oligomer and the interferon-
gamma protein.
• Reliable assay measurements down to 1 pM for protein and 100 pM for DNA demonstrated.
• A general protocol developed for adapting sensor to any of hundreds of commercially available
immunoassay kits AND custom designed DNA sequences.
• A custom cell imaging and incubation chamber for long-term magnetic manipulation of immune
cells.
• A 2D magnetic field array designed for in vitro manipulation of nanoparticle-loaded leukocytes.
• Speeds of 140 µm/s achieved for dynamic nanoparticle movement and 300 µm/s for cell ag-
gregation.
• As a demonstration of cell trafficking, THP-1 lymphocytes loaded with SPION-CpG particles
are magnetically manipulated.
• A passively cooled current controller designed for computer-interfaced control of magnetic
fields.
• Self-healing algorithm and infrastructure (phase rotator, phase detector, RF power sensor,
coupler, DC current sensor, digital control) developed for a power mixer and a high power
amplifier.
1.4 Organization
The thesis is organized as follows. In section 2.1, we introduce a platform for biosensing. Sur-
face chemistry protocols are developed to functionalize a standard IC chip for biological detection.
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Biological protocols are developed using these functionalizations for the detection of proteins and
nucleic acids. In section 2.2, we develop the theory of magnetic particle manipulation. The theory
describing motility in solution is also described. In section 3.2 and section 3.3, we introduce sensing
and actuation of a very different kind: electronic sensors and actuators are designed to “self-heal”
the performance of two IC architectures. In section 3.2, we detail a segmented power-mixer based
mm-wave transmitter capable of multi-Gbps wireless communication. Self-healing capabilities such
as symbol healing and efficiency optimization are introduced. In section 3.3, we present a high power
stacked PA with self-healing capabilities. In chapter 4, we provide a more detailed description of
biological protocols.
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Chapter 2
Magnetic Sensing and Actuation
2.1 A Handheld Magnetic Sensing Platform for Antigen and
Nucleic Acid Detection
2.1.1 Introduction
Point-of-care (POC) diagnostics represents a growing segment of the health care industry [17].
Although many types of sensors have been proposed with high sensitivities, few have demonstrated
the key features that will allow a device to reach widespread use: low-cost, multiplexing, portability,
easily integrated sample preparation, and quick measurement time [18, 19]. In this dissertation,
we present a complete handheld diagnostic device (Fig. 2.1) with two fully implemented assays
for proteins and nucleic acids (Fig. 2.3). It is based on the novel “magnetic freezing” scheme
that removes the need for baseline measurements, allows for multiple sensor measurements, and
eliminates the long warm-up and calibration phases. To the best of our knowledge, magnetic freezing
is a new technique and previously unpublished. We have devised a disposable, low-cost single
chamber cartridge-based approach, which simplifies the sample handling significantly (Fig. 2.1).
We have developed all the necessary surface chemistry to functionalize the surface of a standard
CMOS chip, further reducing the cost and complexity of this handheld diagnostic device. We
also eliminate expensive and bulky infrastructure that limits other sensing technologies such as
microfluidic pumps and optical elements. A crucial component of any POC diagnostic is the biosensor
used to detect biologically relevant targets. Many biosensors have been proposed utilizing optical
(e.g., [50–52]), electrochemical (e.g., [53–60]), mechanical (e.g., [61]), or magnetic (e.g., [24, 62–66])
sensing modalities. Magnetic based platforms enjoy higher sensitivity and virtually non-existent
background due to the absence of strong magnetic properties in most biological samples. The same
magnetic labels can also serve as means of magnetic manipulation during sample preparation (e.g.,
separation, purification, lysing, etc.) in an integrated system [55,63,67–69].
One promising class of magnetic sensors is the complementary metal-oxide-semiconductor (CMOS)
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Figure 2.1: (a) Handheld Diagnostic Device. The device consists of a plug-in cartridge, circuit board,
and single USB data interface cable for communication and power. (b) Disposable Cartridge. The
disposable cartridge consists of an electrically connected integrated circuit chip inside a polypropy-
lene well. (c) Chip Surface after Immunoassay. The chip inside the cartridge has 48 sensor sites and
16 reference sensors. Sensor sites designated by EXP and NC were used for printing the capture
probe or negative control, respectively. Some sensing sites were left blank to examine background
binding. In the DNA and antigen assays, the presence of biological targets leads to the accumulation
of magnetic beads over the sensor.
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frequency-shift based magnetic resonating sensor [24–26]. It relies on detecting the shift in the nat-
ural frequency of a free-running oscillator based on an electromagnetic resonator in the presence of
external magnetic material. The resonator is often implemented on a silicon chip using an inductor,
L, and a capacitor, C, forming an LC resonator. When a magnetic bead is in the vicinity of the
inductor, it increases its inductance, which in turn lowers the resonance frequency. This leads to a
small yet discernible drop in the oscillation frequency that is registered by electronically counting
the number of cycles over one or multiple time intervals. The frequency shift can be correlated to
the number of beads near the resonator. A single-chip array of frequency shift sensors was designed
using integrated circuits (IC) in a CMOS process and previously reported [24]. A novel noise reduc-
tion technique, correlated double counting [25], was used to further enhance the chip’s sensitivity.
This CMOS chip was used to implement the handheld diagnostic reported here. The CMOS im-
plementation is central to a low-cost, low-power implementation of this handheld diagnostic system
due to its highly favorable cost structure in large volumes. The sensor has the benefits of low power,
low cost, and high scalability.
Although the frequency-shift biosensor of Wang, et al. [24] was proposed for potential biological
applications, several important challenges had to be overcome before its widespread deployment. It
was observed that to achieve high accuracy measurements, each sensor oscillator had to be allowed
to run (warm up) for long periods of time up to 30 min. Furthermore, to reduce the detection noise,
the beads needed to be rapidly removed from the sensor surface to obtain a baseline right after the
sample read. This rapid removal was necessary to do the two measurements within a time interval
shorter than the drift time constants of the sensor oscillator. In a realistic biological experiment, the
experimental interval is much longer than the drift time constant due to washing, target binding,
and bead binding. Additionally, replicate measurements on multiple sensors would not allow for
any warm-up time. To remedy these obstacles, we have developed a new technique called magnetic
freezing. By saturating the magnetization of the magnetic beads with a small permanent magnet, the
bead’s effect on the sensor is neutralized. This obviates the need for a baseline measurement before
the experimental assay, thereby reducing frequency drift and improving the sensor signal-to-noise
ratio. Additionally, the sensor does not need to measure during the biological assay.
Another hurdle for widespread adoption is the physical size and cost of the biosensor measurement
equipment. In this design, we have integrated the entire functionality of the sensor onto a reader
printed circuit board (PCB) that in tandem with a processing unit board constitute the entirety of
the reusable unit that connects to USB (Fig. 2.1). We have also designed a disposable open-well
cartridge that combines all sensor sites (48 active and 16 reference) in a single reaction well (Fig.
2.1). The single well allows for easy sample and reagent loading without the need for microfluidic
pumps or structures. This design offers the option to perform the biological assay separately on
a single or multiple disposable cartridges and to plug them (batch processing) into a socket on
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the reader PCB at the conclusion of the biological assay. This approach significantly lowers the
marginal bill materials for the reader to less than $10 and the disposable cartridge to less than
$1 in large volume. In order to demonstrate the viability of the sensor for biologically relevant
assays, we have developed and demonstrated two representative practical assays detecting protein
and nucleic acid targets [70]. We performed these two exemplary assays using our CMOS magnetic
handheld diagnostic reader to detect an interferon-γ protein (relevant for Tuberculosis diagnostics)
and a 31 bp DNA oligomer. This is the first demonstration of complete nucleic acid or protein
assays using a CMOS frequency-shift magnetic diagnostic sensor to the best of our knowledge. All
assays were completed at room temperature without any need for amplification. We demonstrated
detectable concentrations of DNA between 100 pM-10 nM and protein between 1-30 pM in our first
demonstration. Our developed assay incorporates surface chemistry compatible with not only our
frequency-shift biosensor, but also with any standard CMOS IC chip.
2.1.2 Handheld, Portable Cartridge Reader
Our handheld, diagnostic device consists of two major components: a small, disposable cartridge
and the reader (Fig. 2.1). The disposable cartridge consists of the sensor chip mounted on a chip
carrier and protected with a polypropylene housing. The reader consists of a commercial field-
programmable gate array (FPGA) development board (terasIC, Dover, Delaware) with a custom-
designed PCB 2.2. The FPGA provides both power and data channel to the PCB, and bio sensor
chip responds to programming sequence sent from the FPGA with a differential oscillation frequency
of 900Mhz to 1GHz 200mV Vp−p in OUTN and OUTP. The frequency divider chip divides down
the frequency by 22 and converts it to CMOS level(3.3V Vp−p) so that the FPGA will be able to
receive it.
Figure 2.2: Block diagram of digital reader.
The sensing scheme caters to a very simple and small form factor. Data processing consists of a
frequency divider (÷22) and digital counter. Four supply biases are used to bias/power the chip. A
crystal oscillator serves as a frequency reference and clock. The sensing parameters are relayed to
on-chip shift registers. The device communicates to a computer through a single USB cable, which
also provides power to the unit. The entire biological assay is performed in the well of the cartridge.
At the end of the assay, the cartridge is plugged into the reader for data acquisition.
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Figure 2.3: (a) Sandwich Assay for IFN-γ. Surface functionalization consists of an epoxysilane group
to covalenetly attach the capture antibody. The probe antibody binds to a separate epitope of IFN-
γ. The magnetic bead attaches to the probe antibody through a streptavidin-biotin attachment.
(b) Sandwich Assay for DNA oligo. A capture DNA strand complementary to a portion of the
oligo strand is attaches to the PLL surface through electrostatic adsorption. The probe DNA strand
is complementary to a second portion of the target strand and attaches to the bead through a
streptavidin/biotin attachment.
2.1.3 Easy-to-use Open Well Cartridge
The core of our user-friendly interface is allowing for the sample and reagents to be loaded into
a single open reaction well. We have previously demonstrated a microfluidic platform for DNA
binding [24]. However, the requirement for external pneumatic pressure control is restrictive to
a POC solution. Therefore, a well-based design was incorporated to allow the DNA assay to be
conducted by simply filling and emptying the cartridge. Filling the cartridge consisted of pipetting
solution into the cartridge. The foundation of our cartridge is a chip carrier that can be plugged
into a socket on our reader. The IC biosensor chip is attached to the surface of the cartridge using
a conductive silver epoxy (MG Chemicals, Burlington, Ontario, Canada). Next, our chip surface
is functionalized for capture probe attachment. The capture probe and negative control (NC) are
printed onto each of our sensor surfaces using a contact pin based printer (Fig. 2.1). After printing,
the IC chip is electrically connected to the chip carrier by wirebonding from electronic pads to the
chip carrier leads. To provide structural support and waterproofing for the wirebonds, a two-part
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Figure 2.4: A low-cost, disposable cartridge is designed to house the sensor array. It consists of a
chip carrier used to enable plug-and-play feature inside the reader. The sensory array is electrically
connected to the carrier and a well is formed above the carrier.
epoxy is applied to the wirebonds. The surface is heated to 80◦C for 10 min before epoxy application
to remove adsorbed water and ensure a good seal [71]. Finally, the polypropylene housing is epoxied
to the chip carrier to form the open well. After fabrication, the cartridge can be stored in 4◦C
storage until the assay needs to be performed.
2.1.4 Magnetic Freezing
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Figure 2.5: (a) The Magnetic Freezing Effect is analogous to (b) an oscillating mass. In a param-
agnetic state, the magnetizations of the beads (Mbead) are allowed to oscillate up and down. When
the small external magnet is applied, the magnetization saturates. The saturation prevents the
oscillation of the beads’ internal magnetization and no longer contributes to the inductance change
of the frequency shift sensor.
2.1.5 Surface Chemistry of Integrated Circuits (IC) for Biological Sam-
ples
A key component of constructing the cartridge is the functionalization of the IC chip’s silicon nitride
surface. Although silicon nitride’s non-reactivity serves as a great passivation layer for the IC chip,
it presents a challenge to functionalizing the surface. In order to attach molecules to this inactive
surface, a 2 µm layer of glass was deposited to the surface using a plasma-enhanced chemical vapor
deposition (CVD). The deposition also reduces surface roughness. Our surface functionalization
allows capture DNA strands or antibodies to bind to the surface of the chip. Various other function-
alizations were evaluated to have lower binding density and uniformity. The protocols are detailed
in the Appendix.
Different functionalizations were used to prepare the silicon chip for either DNA capture strand
or capture antibody attachment. Several attachment chemistries for antibody and nucleic acid
attachment are commonly used for microarray applications including hydroxyl, poly-L-lysine (PLL),
amine, aldehyde, and epoxy coatings. The protocol was modified from existing microarray protocols
[72–78]. For DNA attachment, a PLL surface is used to allow for the electrostatic adsorption of
DNA. Of these coatings, the amine coating of the PLL surface has the highest binding density,
sensitivity, and uniformity. To deposit the PLL layer, first, the chip was plasma etched for 1 min
to increase reactivity of deposited glass to increase PLL density. Next, the chip was incubated for
30 min in a PLL solution consisting of 37.5 ml nanopure water, 10.1ml filtered 1X PBS, and 8.8
ml PLL from Sigma-Aldrich (St. Louis, MO). The functionalized chip is then stored in a desiccator
and allowed to sit for 2 weeks to cure the poly-L-lysine, thus increasing hydrophobicity.
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For antibody attachment, an epoxy surface was prepared to allow for covalent attachment to the
capture antibody. The chip was immersed for 10 min in 3M H2SO4 followed by 10 min of 3M HCl.
Immediately after, it was rinsed with water and dried with compressed nitrogen gas [76]. The chip
was immersed in 2% (3-Glycidyloxypropyl) trimethoxysilane (Sigma, Aldrich) in 95% ethanol for 15
min. Then it was rinsed with ethanol to remove unbound epoxide groups. The chip was then dried
with nitrogen and baked at 110◦C for 15 min for covalent attachment of silane groups to the glass
substrate [50].
Figure 2.6: Magnetic Freezing. To illustrate the effect of magnetic freezing, a sensor with beads (a)
and without beads (b) is measured over a much longer time period than typical data acquisition.
After the magnet is placed under or removed from the sensor, an immediate shift in frequency occurs.
This difference in frequency shift is used to quantify magnetic beads over the sensor.
2.1.6 Probe Printing
After creating a chemically reactive surface on our IC chip, we need to print experiment-specific
attachment probes to our sensor surface. For the DNA sandwich assay, synthetic oligo probe strands
(IDT, Skokie, IL) were used for attachment to the PLL surface. The probes were printed onto the
chip surface using the SpotBot 2 contact pin based microarray printer (Arrayit, Sunnyvale, CA) (Fig.
2.7). The print solution was composed of 10 µl of 2X microspotting solution (Arrayit, Sunnyvale,
CA) with 10 µl of 50 µM probe DNA . The chip was then allowed to dry overnight in a desiccator.
Next, the chip was baked at 80◦C for 80 min to further dry the chip and enhance DNA binding.
Following printing and drying, the chip was placed in a container with BlockIt Plus Microarray
Blocking Buffer (Arrayit, Sunnyvale, CA) and placed on an orbital shaker for 1 hr at 100 rpm.
Finally, the chip was lightly rinsed for 30 s in nanopure water and spun dry.
For the Immunoassay, antibodies were printed using the SpotBot 2 microarray printer at room
temperature. Humidity level was maintained between 50-55%. Print solution was prepared by
mixing 10 µl stock solution of antibodies with 10 µl of protein printing buffer (ArrayIt, Sunnyvale,
CA). Protein solution buildup in the pin reduced the uniformity of the printed spots on the sensors.
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Thus, the pin was routinely cleaned prior to printing by sonication in 50mM KOH from 10 min to
1 h [79]. After printing every 10 spots, the pin was sonicated for 10 min in distilled H2O, ArrayIt
light pin cleaning protocol [80]. After printing antibodies on the sensors, the chip was left in the
desiccator to dry overnight.
Figure 2.7: A microarray printer is modified to align print spots on the surface of the sensors.
Figure 2.8: A distribution of 4.4µm beads over the sensor surface.
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Figure 2.9: Magnetic Freezing Quantification of 4.5 µm beads. The average frequency shift for each
4.5 µm bead is 12.8 kHz. The coefficient of determination, R2, was greater than 0.99.
2.1.7 DNA Protocol
After probe printing, the chip can be stored until a sample is ready to be tested. To test the
viability of the instrument for the quantification of unique DNA targets, we employed a sandwich
assay consisting of a capture (5’-TTT TTC TGG TTG GGT TGA TTG GAT TTA GCT TGG
C-3’), target (5’-ATC CAA TCA ACC CAA CAA TAT TGA TAA GGA T-3’), and a biotinylated
probe strand (5’-Biotin-ATC CTT ATC AAT ATT-3’) for indirectly labeled detection. A non-
complementary NC capture strand (5’-ATG CGA AAC GAT CCT CAT CCT GTC TCT TGA-3’)
is also printed to test cross binding.
The hybridization assay took place within the open well. Emptying the well consisted of gently
inverting the well. Buffers used in the assay were a hybridization buffer (1X PBS, 1mg/mL BSA,
5nM EDTA, 0.1% Tween-20, 0.1mg/mL salmon sperm DNA), a Bead Binding and Washing Buffer
(5mM Tris-HCl pH 7.5, 0.5mM EDTA, 1M NaCl), Stringent Wash Buffer 1 (Arrayit, Sunnyvale,
CA), and Stringent Wash Buffer 2 (Arrayit, Sunnyvale, CA). First, the dry well was washed 3
times with Hybridization Buffer. Next, a hybridization solution containing varying concentrations
of target DNA and 1 µM biotin labeled probe DNA was prepared. A total of 200 µl of hybridization
solution was added to the well and allowed to incubate at room temperature for 30 min. During
hybridization, a solution of streptavidin conjugated 1µm diameter super-paramagnetic beads was
prepared. Ten µl of 10 mg/ml Dynabeads MyOne Streptavidin C1 (Invitrogen, Carlsbad, CA) was
washed and resuspended 3 times in 100 µl of Binding and Washing Buffer per the manufacturer’s
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protocol [81]. After DNA incubation, the well was rinsed twice each in DNA Stringent Wash Buffer
1 and 2 (Arrayit, Sunnyvale, CA) for 2.5 min at a time. The well was then rinsed 3 times in Binding
and Washing Buffer. The bead solution was added and allowed to bind for 20 min. Lastly, the well
was washed another 3 times with Binding and Washing Buffer, then washed 3 times with nanopure
water, and then emptied. A more detailed protocol can be found in the Appendix section “Detailed
DNA Functionalization of IC.”
Figure 2.10: Scanning electron microscope image of beads over our sensor. These beads were counted
and compared with measured signal. Each contiguous colored group represents 100 beads.
2.1.8 Immunoassay Protocol
IFN-γ and Granulocyte-macrophage colony-stimulating factor (GM-CSF) ELISA MAX Standard
kits were obtained from Biolegend (San Diego, CA). IFN-γ capture antibodies were used for the
primary assay. GM-CSF capture antibodies were used as negative control. Assay dilutent (1% BSA
in PBS) was prepared prior to use. Lyophilized IFN-γ protein was reconstituted in assay dilutent
and stored in a -80◦C freezer in polypropylene vials. The chip was removed from the desiccator and
blocked for 1 h in 500 µl of BlockIt Plus solution (ArrayIt, Sunnyvale, CA) in an orbital shaker at
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125rpm. Afterwards, the chip was rinsed 5 times with 400 µl of Wash Buffer (0.05% Tween-20 in
PBS) to remove the blocking solution. The IFN-γ stock solution was thawed and diluted to the
target concentration. A total of 100 µl of protein solution was added to the well and incubated for
2 h at room temperature with shaking at 125rpm. The well was rinsed 5 times with 400 µl of wash
buffer to remove unbound proteins. IFN-γ detection antibody (200X dilution of stock solution in
assay diluent) was added to the well and incubated for 1 h at room temperature with shaking at
125rpm. Unbound capture antibodies were washed 5 times with 400 µl of wash buffer. A total of 5
µl of 1 µm diameter Dynabeads MyOne Streptavidin C1 coated magnetic beads was washed 3 times
with PBS to remove preservatives from the bead solution [81]. The beads were then resuspended
in 100 µl of PBS. Afterwards, the bead solution was added to the well and was incubated for 20
min with no agitation. After incubation, 5 µl of 25% Glutaraldehyde solution (Sigma-Aldrich, St.
Louis, MO) was added to the well for fixation [82]. After a 10 min incubation, the well was rinsed
5 times with wash buffer. Finally, the well was rinsed 5 times with water to prevent crystallization
of remaining salt solution on the chip. The chips were left to dry for measurement.
Figure 2.11: Magnetic Freezing Quantification of 1 µm beads. These beads were used in the DNA
assay and immunoassay. The average frequency shift for each 1 µm bead is 136 Hz.
2.1.9 Measurement and Processing
Following the hybridization assay, the chip can be measured while immersed in solution or dry. If
allowed to dry, the chip could be measured months after the hybridization assay with less than
1% change in measurements. The reader is connected to an external laptop and a graphical user
interface is initiated. Measurement consists of two cycles of measurements. The time to obtain a
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single measurement is 100 ms for a combined reference and sensor measurement. During a cycle,
each sensor is measured for 5 s for a total of 50 measurements per sensor. All measurements had
a standard deviation of less than 20 Hz. Between 1-48 sensor sites can be measured, within up to
4 min for all 48. One cycle of measurements establishes the baseline frequency in the presence of
a small rare-earth magnet. Next, the magnet is removed from the PCB. During the next cycle of
measurements, the endpoint frequency measurement is obtained.
The difference between the baseline measurement and the endpoint measurement is used to infer
the number of beads over the sensor. More bead binding implies a higher concentration of target
analyte. A graphical user interface is used to acquire the data and initiate function (Fig. 2.12).
Figure 2.12: DNA Quantification. In the DNA assay, target concentrations can be detected from
100 pM to 10 nM. At the limit of detection, 100 pM, the frequency shift from the target sensor is
over two times the shift from a non-complementary NC sensor.
2.1.10 DNA Sandwich Assay
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Figure 2.13: DNA Quantification. In the DNA assay, target concentrations can be detected from
100 pM to 10 nM. At the limit of detection, 100pM, the frequency shift from the target sensor is
over two times the shift from a non-complementary NC sensor.
2.1.11 Data Processing
The simple processing scheme obviates the need for high computational power or filtering schemes.
A simple arithmetic division is the heart of the signal processing. The presence of magnetic beads
leads to a shift in the resonant frequency. The resonant frequency is determined directly from the
number of periods over the measurement time. Optimal counting intervals have been previously
explored [25].
Magnetic freezing is a novel technique that adds functionality to and improves performance in
frequency-shift based magnetic biosensors. We previously demonstrated the large linear dynamic
range of the sensor to magnetic beads as well as single bead sensitivity [24]. Techniques such as
incorporating a reference sensor and a correlated double counting scheme reduced a very large frac-
tion of frequency drift. Traditionally, a frequency-shift oscillator based magnetic biosensor without
magnetic freezing requires approximately 30 min of warm up time for the oscillator to become stable.
Moreover, frequency drift in oscillators compounds this problem by increasing the noise of the sen-
sor. In the previous detection scheme, sensitivity of the biosensor was determined by the immediate
presence or absence of magnetic beads over the sensor. This would obviate long-term frequency drift
by obtaining frequency shift measurements immediately after the baseline measurement. However,
this is not compatible with a typical biological assay. In a biological assay, the baseline measure-
ment would need to be acquired before the entire assay, with the final measurement needing to be
taken at the conclusion of the assay. This would allow significant oscillator drift to accumulate, thus
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significantly decreasing sensitivity. In addition to the requirement that the biosensor would need to
stay on during the entire assay, the system would be incapable of conducting measurements over
multiple sensors because only one sensor could be maintained active during the assay.
Magnetic freezing solves all these issues (elimination of warm up, removal of active requirement
of the system during assay, elimination of baseline measurement before assay, inability to obtain
measurements from multiple sensors) by requiring only one set of measurements at the conclusion
of the assay. This is accomplished by first measuring the sensor at the end of the assay using the
previously described frequency shift technique, as seen in Fig. 2.5. In an unfrozen state, the beads
are able to track the magnetization induced by the inductor. Next, an external magnet is used to
saturate the magnetization of the bead. This holds the magnetization to a point of saturation. The
magnetic field of the inductor cannot modulate the magnetization vector of the beads due to the
magnetic saturation of the beads. Thus, the beads have no significant effect on the inductance. A
small (9.5mm x 9.5mm x9.5mm) neodymium magnet with a surface field of 0.5T is used to saturate
magnetization. By having magnetization saturated, the magnetic domains inside the bead are not
allowed to track the 1GHz oscillation frequency of the inductor. This prevents the beads from
increasing inductance and lowering the resonant frequency of the electrical oscillator.
To examine the effect of magnetic freezing, an experiment was conducted by randomly distribut-
ing between 1-250 4.5 µm diameter beads (for ease of counting) over the sensor surface. An external
magnet was attached and removed from underneath the sensor. For demonstration of the magnetic
freezing effect, a sensor is measured continuously for 120 s. At t=30 s, the small magnet is placed
underneath the sensor and PCB (Fig. 2.6). The shift in frequency is immediate, limited only by
how quickly one can place the magnet. The baseline measurement is taken by calculating the mode
of frequency shift over a few seconds. The noise before the shift is calculated by computing the stan-
dard deviation of the data. After removing the magnet at t=60 s, the mode and standard deviation
is again calculated over a period of a few seconds. This experiment was repeated for all 48 sensors
and the results are shown in Fig. 2.9 and Fig. 2.8. An average frequency shift of 12.8 kHz per bead
was measured. A shift was detected for a quantity of beads between 1-250. The limit of detection
can be seen to be a single bead. The sensor did not show any signs of saturation. Experimental
data and electromagnetic simulation revealed that the sensor could have beads stacked up to 40 µm
above the sensor surface before saturating (Fig. 2.20). For biological studies, paramagnetic beads of
1 µm diameter were used for the protein and nucleic acid assays. To quantify the beads, sensors were
imaged using a scanning electron microscope. The number of beads over the sensor were counted
(Fig. 2.10) and compared with measured signal. The quantification of these beads is shown in Fig.
2.11.
An important trend in biotechnology is the emergence of nucleic acid testing (NAT) [22]. Areas
with the printed capture strand would result in beads binding to the sensor surface, as seen in Fig. 1c.
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Conc. Conc. Exp. Freq. NC Freq.
(nM) (pg/mL) Shift (kHz) Shift (kHz)
10 5000 730 18
1 500 409 6
0.5 250 293 30
0.1 50 54 26
Table 2.1: Frequency-shift measurements versus frequency for the DNA assay.
Reference sensors and sensors printed with the NC capture strand would exhibit some fluctuations
in frequency shift measurements due to variations in background bead binding to the chip. However,
the NC sensors did not appear to have a different level of binding than the background binding level,
indicating little or no cross binding of the sandwich assay.
Quantifiable target DNA concentrations could be detected over two orders of magnitude (Fig.
2.13 and Table 2.1). The limit of detection for the sensor was 100 pM, where the frequency shift
was more than two times the background level. The sensor reached a saturation level at 10 nM.
Although this sensitivity is less than traditional amplification-based technologies, this device did
not depend on the stringent heating/cooling cycles of amplification technologies. This allows for a
simpler, more reliable detection system.
2.1.12 Immunoassay detection of Tuberculosis biomarker IFN-γ
Although NAT testing has demonstrated significant progress in diagnostics, a more diverse variety
of biomarkers can be detected with traditional immunoassay. To test the biological impact of the
sensor, the TB biomarker IFN-γ was detected as well as its cross-binding with a GM-CSF capture
antibody. Compared with the DNA assay, the immunoassay had a higher level of background binding
and variability. The results of the immunoassay are shown in Fig. 2.14 and Table 2.2. The minimum
detectable concentration of protein was 1 pM. The sensor saturated at approximately 30 pM. Two
additional concentrations were measured outside of the quantifiable range of the ELISA kit: 60 pM
and 150 pM. It is important to note that even though a single antigen was detected using a standard
sandwich ELISA kit, the IC surface chemistry and detection system are compatible with any other
sandwich immunoassay.
2.1.13 Cartridge Variability
A reliable diagnostic should yield the same measurements for the same target concentration. Various
sources of variability affect overall cartridge variability: electronic chip-to-chip variability, capture
strand/antibody print alignment, and biological assay variability. All three of these variability
sources contributed to the overall DNA assay and immunoassay quantification variability. Due to
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Figure 2.14: Immunoassay Quantification. The limit of detection for IFN-γ was approximately
1pM. The sensor surface was saturated with beads at 30 pM. The negative control (NC) consisted
of sensors sites printed with an antibody specific to Granulocyte-macrophage colony-stimulating
factor (GM-CSF). Two additional concentrations were tested at 60 pM and 150 pM. However, these
concentrations were outside the quantifiable range of the ELISA kit and therefore not as reliable.
the nature of contact printing, variations in spot printing could be misaligned by as much as 50 µm.
This misaligns capture molecules over the sensor and thus reduces the number of magnetic beads
detected. This leads to an underestimation of target molecules.
In order to quantify chip-to-chip variability, the same number of beads must be measured across
multiple cartridges. A total of eight separate cartridges were measured. First, cartridges were
measured with no beads present. This leads to a standard deviation of less than 4kHz, or the
equivalent of less than 30 beads.
Next, we attempt to place a constant number of beads on the same sensor of the eight cartridges.
The tip of a wooden probe is coated with a solution of 1 µm magnetic beads, and subsequently, a thin
Conc. Conc. Exp. Freq. NC Freq.
(pM) (pg/mL) Shift (kHz) Shift (kHz)
150 2500 1080 74
60 1000 740 30
30 500 1250 -117
10 200 1020 68
6 100 630 0
2 40 220 -3
1 20 330 48
Table 2.2: Frequency-shift measurements versus frequency for the immunoassay.
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Figure 2.15: In order to isolate each cartridge’s variability in quantifying beads, it is necessary to
ensure each cartridge measures the same quantity of beads. A distribution of beads is fixed to the
tip of a non-magnetic wooden probe using a synthetic polymer resin. The probe is visually aligned
to a sensor on each cartridge and frequency shift measurements are obtained.
layer of synthetic polymer (Sally Hansen, New York, NY) to permanently attach the beads. Both the
wooden probe and nail polish have a negligible effect on the sensor because they are non-conductive
and nonmagnetic. The probe is visually aligned to the surface of the sensor for each cartridge and
measured (Fig. 2.15). The results of the cartridge-to-cartridge variability are shown in Fig. 2.16.
The standard deviation of the probe measurements is significantly higher than those of blank car-
tridge measurements. However, the standard deviation of the probe measurements is approximately
10% of the overall signal. This corresponds to approximately 10 µm of probe misalignment for our
120 µm diameter sensor. Thus, the variation is likely due to probe misalignment.
2.1.14 Limitations of dB/dz for Label-free Detection of Nucleic Acids
A general method for the label-free detection of a nucleic acids is proposed 2.17.A hybridization event
results in the label having an average position closer to the sensor surface. The scheme depends on
the ability for the sensor to discriminate how closely the label travels near the sensor surface.
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Figure 2.16: Cartridge-to-Cartridge Variability. An important metric of a diagnostic is its ability to
reproducibly detect the presence of a fixed number of target molecules. To emulate a fixed number of
target molecules, the average frequency shift of eight cartridges are measured with similar numbers
of magnetic beads. First, the cartridges’ variability is measured with no beads present. A standard
deviation of 4 kHz was measured. Next, a probe with a fixed number of beads was measured on
each sensor. A standard deviation of 150 kHz, or 10% of the overall signal was measured. This is
likely due to probe-sensor misalignment.
Figure 2.17: Method for the label-free detection of nucleic acids.
Although this detection method could be extremely useful because of the elimination of the need
for labeling, this detection scheme is difficult to realize in frequency-shift oscillator-based biosensors.
The detection scheme relies on the ability to discriminate proximity changes of the magnetic label
to the sensor surface.
An experiment is conducted to measure the vertical sensitivity of a frequency-shift biosensor to
vertical displacement of magnetic particles. The tip of a non-magnetic wooden probe was coated
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Figure 2.18: To test the vertical sensitivity of the sensors to beads, a toothpick containing beads
on the tip was moved at varying positions above the sensor using a micrometer. As a control, a
toothpick without beads was measured at the same heights.
with superparamagnetic particles (Fig. 2.15). The probe was positioned above the sensor surface
using a micrometer positioner. The sensor is measured at various displacements above the sensor
surface. Additionally, electromagnetic simulations are conducted to estimate the vertical sensitivity
of the biosensor (Fig. 2.19). The results of the experiment and simulation are plotted in Fig. 2.20,
showing positive agreement.
Figure 2.19: Additionally, an electromagnetic simulation was used to determine the vertical sensi-
tivity of the sensor to magnetic beads.
It can be seen that the sensor has a “volume” of detection of approximately 40µm above the
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Figure 2.20: The results of the simulation and experiment reveal a 10%, 50%, and 90% reduction in
sensitivity at bead heights 3µm, 13µm, and 40µm above the sensor surface, respectively
sensor surface (Fig. 2.21). However, this displacement would be difficult to realize in the label-free
detection scheme because the probe strands would need to be too long (thousands of basepairs long)
for detection. Despite this limitation, the volume of sensing can be potentially used to increase
the dynamic range and sensitivity of the frequency-shift biosensor by using a composite structure
above the sensor surface (such as a porous membrane or cellulose chamber) to enhance the binding
of magnetic labels above the sensor.
Figure 2.21: Only a fraction of the total sensing volume is used in the surface binding-based approach.
Future designs could utilize the full sensor volume and expand the dynamic range of the sensor.
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2.1.15 Additional Label-free Detection Schemes
Additional label-free detection schemes are proposed. In a scheme called the “bead release assay,”
the hybridization of a target nucleic acid strand prevents a secondary labeled probe strand to bind
to the primary probe strand (Fig. 2.22). This is similar to a competitive immunoassay. The target
strand hybridization must be energetically favorable to the secondary probe strand hybridization.
However, if the target strand is not complementary to the primary probe strand, the secondary probe
strand is hybridized and the magnetic label binds to the sensor surface. Unlike previous detection
schemes, the presence of magnetic labels near the sensor surface is indicative of the lack of target
strands in the biosample.
Figure 2.22: Bead release assay. Presence of complementary target strand prevents magnetic labels
from binding to the sensor surface.
The energetics of this detection scheme was simulated using a thermodynamic modeler [83]. The
primary probe strand (5’-GACTTGCATCA TACTACAACGTCGTCCGTTT AAGGGCCCAGC-
TAGGATCA3’ ) and target strand (5’ TGATCCTAGC TGGGCCCTTAAACGGACGACGTTGT
AGTATGATGCAAGTC-3’) dimer was more energetically favorable (-16.35kcal/mol) than the probe
strand and secondary probe strand (5’-TGATCCTAGC-3’) dimer.
We demonstrate the bead release assay on a glass slide (Fig. 2.23). We also demonstrate the dose
response of target strands and the resulting difference in binding level (Fig. 2.24). The limitation
of the bead release assay is a low dynamic range.
We propose additional potentially label-free schemes [84]. In Fig. 2.25, a hybridization event
results in a change of persistence length of the nucleic acid. This results in discernible aggregate
motion of the particle because its positional distribution is changed. In a separate scheme (Fig.
2.26), target strand hybridization results in the opening of a nucleic acid hairpin structure. The
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(a)
(b)
Figure 2.23: Demonstration of bead release assay for (a) noncomplementary and (b) complementary
target.
bead is released from a positional distribution near the sensor surface. In a variation of an earlier
label-free sensing scheme, the lateral sensitivity of a sensor is exploited to lead to signal change (Fig.
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Figure 2.24: Dose response of bead release assay. Results show a steep transition in bead binding
from 4 nM to 0.04 nM target concentration.
2.27).
Figure 2.25: Persistence length change of a hybridization event leads to a change in position distri-
bution of the label.
Figure 2.26: Target hybridization leads to the opening of a nucelic acid hairpin structure.
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Figure 2.27: An external force (for example flow, gravity, or magnetic) is used to exploit the lateral
sensitivity of the sensor and lead to signal change.
2.1.16 Variations of Magnetic Freezing
Magnetic freezing enables the elimination of a baseline measurement before or during the biological
assay. In addition, the effect of oscillator frequency drift is significantly reduced. In our previously
mentioned magnetic freezing scheme, a small magnet is placed near the center. In a POU diagnostic,
this magnet could be integrated into the device lid. The presence of the magnet saturates the
superparamagnetic particles and neutralizes their effect on the biosensor. The saturation of the
biosensor as a function of magnet displacement is examined. The external magnet is placed above
the sensor and its vertical position is varied using a micrometer positioner (Fig. 2.28). The magnet
starts at a position a cm above the sensor . Next, the magnet is moved up 10 mm, then returned
to its starting position. Subsequently, the magnet is moved up vertically in steps of 3mm, then
returned in steps of 3mm. Finally, this process is repeated for steps of 2 mm, and then 1mm. The
results of this shift is shown in Fig. 2.29. The saturation profile can be seen from the results.
An alternative saturation and unsaturation could be achieved using a permanent magnet rotated
using a small motor without any rotational encoder or positional feedback mechanism (loosening the
tolerance requirements of the motor and reducing cost) (Fig. 2.30). The sensor response is shown
in Fig. 2.31a. The FFT of the signal is shown in Fig. 2.32a. Low frequency drift in oscillator
signal and motor speed drift is filtered using a band pass filter centered on the peak frequency. A
script was written to automatically calculate the peak frequency and adjust the bandpass filter. The
filtered frequency response is shown in Fig. 2.32b. The filtered signal is shown in Fig. 2.31b. A new
signal was constructed using the maximum and minimum values of both the unfiltered and filtered
signal (also the amplitude of the signal envelope). The new resulting signal is shown before and
after filtering (Fig. 2.33). As can be seen, the noise in the signal is suppressed using filtering.
An alternative to filtering and envelope detection of the motorized magnetic freezing scheme is
a method similar to lock-in amplification. A script automatically determines the peak frequency
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Figure 2.28: To test sensitivity of magnetic freezing to magnet placement, a magnet’s position is
varied vertically above the sensor.
Figure 2.29: Demonstration of vertical sensitivity of saturating magnet. The magnetic saturation
curve can be seen from this graph.
power of the FFT of the signal (Fig. 2.34a). Next, the signal is multiplied by a sinusoid in the time
domain. Assuming proper phase shift, the multiplication of the sinusoid and signal should correlate
to beads over the sensor. However, the proper phase shift is difficult to ascertain. Thus, the original
signal is multiplied with many sinusoids of varying phase shifts, and a maximum convolution power
is obtained. The convolution power versus beads over the sensor is shown in Fig. 2.34b. As can be
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Figure 2.30: Variation of magnetic freezing using a rotating magnet.
seen, the resulting signal is more linear than the previous detection scheme.
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(a)
(b)
Figure 2.31: Sensor response to motorized magnetic freezing (a) before and (b) after filtering.
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(a)
(b)
Figure 2.32: FFT of sensor response to motorized magnetic freezing (a) before and (b) after filtering.
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(a)
(b)
Figure 2.33: Bead quantitation of motorized magnetic freezing(a) before and (b) after filtering.
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(a)
(b)
Figure 2.34: Lock-in amplification of motorized magnetic freezing (a) FFT and (b) quantitation.
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2.1.17 Absolute Oscillation Frequency of Biosensor Array
In the frequency shift biosensor, two frequency differences are calculated. The first difference is
between the absolute frequency of the sensing inductor and that of the reference inductor. This is
done to reduce correlated noise in measurements. The second difference is an additional subtraction
between the previously mentioned reference difference and the same difference while the sensor
is magnetically frozen (baseline measurement). The difference between the reference and sensing
inductor has an offset. Experiments are conducted to discern the source of this offset. The source
of these fixed offsets are due to a process dependent capacitance variation in the IC. However, fixed
offsets do not impact the final signal from the system.
The biosensor array is shown in Fig. 2.35. The absolute frequency difference can be seen in Fig.
2.36. To analyze the trend of the absolute oscillation frequency, the mean and standard deviation
of aggregate columns are plotted (Fig. 2.37a). The sensors are 16 repeated standard cells of a
VCO. Therefore, the trend in oscillation among the pairs should correspond with the separation of
the VCOs: 360 µm. Where would the capacitors of the second, 4th, and 6th rows have be located
such that there exists a constant gradient of capacitance, and thus a constant gradient of oscillation
frequency? The repositioned rows are shown in Fig. 2.37b. The new separations distances were
drawn with a ruler to the right of the biosensor array (Fig. 2.35a). By juxtaposing the ruler to
approximately the center of mass of the first capacitor, we can see the other rulers line up to the
center of mass of subsequent capacitors. This implies that a process gradient leads to a linear
dependency of capacitance, and thus resonant frequency.
2.1.18 Conclusion
We have presented a low-cost, low-power, amplification-free, handheld diagnostic platform for point-
of-care diagnostics. The platform consists of a disposable cartridge containing 48 sensor sites in
an area of 3 mm2. The cartridge can be easily and cost effectively scaled for more sensor sites
without increasing the size or cost of the platform. The platform requires no bulky or expensive
infrastructure such as microfluidic pumps or optical elements. Scanning time consists of 10 s per
sensor site at the conclusion of the biological assay and requires no calibration or warm-up. All
sites are contained in a single reaction well for ease of use and we have demonstrated specificity of
capture oligomers and antibodies for a target DNA sequence and IFN-γ. We have demonstrated
simultaneous measurement of multiple sensing sites and believe this could be extended to enable
spatial multiplexing of multiple targets. Commercial products exist [81] for magnetic bead extraction
of genomic DNA from whole blood at concentrations greater than 1 nM. Additionally, our technology
could be coupled with various isothermal DNA amplification techniques for applications that require
increased sensitivity [22]. Both DNA and antigen targets are compatible with the detection system.
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(a)
(b)
Figure 2.35: (a) Layout of biosensor array and (b) zoomed picture. Capacitors are colored purple.
To use the sensing platform, a user plugs in the prefabricated cartridge specific to the cartridge
reader. Next, the assay The platform has been demonstrated to be capable of indirectly-labeled
detection of DNA to 100 pM and IFN-γ antigen to 1 pM. The sensor sites can be used to detect
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Figure 2.36: Frequency shfit of each sensor in the biosensor array. The actual frequency shift is the
plotted value added to 960MHz. A row-dependent linear gradient of oscillation frequency can be
seen.
multiple unique targets or replicate targets for higher fidelity. This platform leverages the research
and development in magnetic bead manipulation, thus allowing the technology to be compatible with
magnetic bead based sample preparation. We have also developed a reliable protocol to functionalize
DNA oligomers and antibodies to CMOS based sensors. The same protocols can theoretically be
applied to many different DNA sequences or one of hundreds of commercially available sandwich
immunoassay kits. We have introduced a measurement technique called magnetic freezing to improve
noise performance, eliminate the need for a baseline measurement, and decouple the biological assay
from scanning. Because our reader was constructed with standard electronics that can be integrated
onto IC chips, the entire measurement system could consist of just the disposable cartridge with a
small battery. These milestones enhance the POC viability of the magnetic frequency shift biosensor
and future silicon IC biosensors. The sensor can be combined with lateral flow or microfluidics 2.38
for integrated sample preparation.
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(b)
Figure 2.37: (a) Average row frequency shift and standard deviation. (b) Repositioned row place-
ment for a linear fit between row spacing and linear frequency shift response.
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Figure 2.38: The biosensing platform is demonstrated with integrated microfluidic channels.
2.2 DPMF for Trafficking of Activated Macrophages for Brain
Tumor Therapy
2.2.1 Introduction
Malignant brain and central nervous system tumors have dismal median survival rates between 1-2
years [3]. Immunotherapy utilizing functionalized nanoparticles has been shown to be a promising
treatment for intracranial gliomas, the most common type of malignant brain tumor [85]. However,
the retention and delivery of immune cells and nanoparticles to the tumor site remains a hurdle
of immunotherapy. We propose a method for magnetically delivering nanoparticles and cells to
a target site. The ability to control the location of immune cells during or following activation
would represent a powerful new technique for this field. Targeted magnetic delivery is emerging
as a technique for controlling cell movement and localization. Here we show that this technique
can be extended to microglia, the primary phagocytic immune cells in the central nervous system.
The magnetized microglia were generated by loading the cells with super paramagnetic iron oxide
nanoparticles (SPION) functionalized with CpG oligonucleotides to form a SPION-CpG construct1.
This serves as a proof of principle that nanoparticles can be used to both deliver an immunos-
timulatory cargo to cells and control the movement of the cells. The nanoparticle-oligonucleotide
conjugates are efficiently internalized, non-toxic, and immunostimulatory. We demonstrate that
the in vitro migration of the adherent, loaded microglia can be controlled by an external magnetic
field, and that magnetically-induced migration is non-cytotoxic. Analysis of cell movement velocities
1This project was the product of a truly amazing collaboration with Behnam Badie, Jacob Berlin, Ethan White,
Torkom Pailevanian, Kaushik Dasgupta, Darya Alizadeh, Pengpeng Cao, Yiming Weng, Anil Suresh, Desiree Van
Haute, and Jeff Sherman. This contribution of this work was primarily in developing the cell box apparatus, trafficking
analysis, magnetic control, and image processing.
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clearly demonstrates increased cell velocities toward the magnet. These studies represent the initial
step towards our final goal of using nanoparticles to both activate immune cells and to control their
trafficking within the diseased brain. In order to capture videos of this magnetically-induced migra-
tion of loaded cells, a novel 3D-printed cell box was designed to facilitate our imaging application.
We present a scaled-down proof of concept for this manipulation system while easily tracking particle
and cell locations. This prototype is a complete cell-culturing system capable of manipulating and
imaging cells loaded with magnetic nanoparticles (Fig. 1.10). The system can dynamically actuate
over a wide variety of magnetic field profiles and can toggle between them (Fig. 2.39b). Moreover,
this system provides a research tool for the magnetic manipulation of cells and particles in a bulk
media solution. Magnetic particle manipulation has seen a large growth of applications among basic
science measurements using magnetic tweezers [86], cell separation [87], and tissue engineering [88].
However, these systems have small active areas and require complicated setups, and are costly, un-
scalable, and difficult to image [89]. By manipulating cells contained in a petri dish of cell media,
problems related to lack of cell media and nutrients are alleviated. This enables long-term cell ex-
periments of bulk cell populations with identical environmental conditions. The compact system is
designed to fit onto a standard 100 mm diameter petri dish. The system is compatible with a wide
variety of inverted microscopes for live-cell imaging with bright-field or fluorescence microscopy. We
also developed a protocol for the loading of magnetic nanoparticles in human monocytes (THP-1).
We use these capabilities to magnetically actuate the monocytes while simultaneously imaging and
culturing them (Fig. 2.42b).
2.2.2 Magnetic Trafficking Calculations
2.2.2.1 Review of Magnetics
It is useful to consider the units of quantities involved in magnetics calucations [90].
Magnetostatic equations can be derived from Maxwell’s equations,
∇ ·D = ρ (2.1)
∇ ·B = 0 (2.2)
∇×E = −∂B
∂t
(2.3)
∇×H = J + ∂D
∂t
(2.4)
where D is the displacement field, E is the electric field, J is the current density, and ρ is the
charge density.
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Quantity Symbol CGS units Conv. factor SI units
Magnetic flux density B gauss (G) 10−4 tesla (T) = Wb/m2
Magnetic flux φ G · cm3 10−8 weber (Wb) = volt sec (Vs)
Magnetic field strength H oersted (Oe) 103/4pi A/m
Volume susceptibility χ dimensionless 4pi dimensionless
Mass susceptibility ρ cm3/g 4pi × 10−3 m3/kg
Permeability µ dimensionless 4pi ×10−7 H/m
Relative permeability µr not defined - dimensionless
Demagnetization factor D dimensionless 1/4pi dimensionless
Table 2.3: Magnetic Units
In magnetostatics, these equations reduce to,
∇ ·B = 0 (2.5)
∇×H = J (2.6)
2.2.2.2 Field Calculations from a Dynamically Controlled Grid
For steady currents, the magnetic flux density can be explicitly calculated using the differential form
of the Biot-Savart (or Biot-Savart-Laplace) law,
dB =
µ
4pi
Id`× rˆ
r2
(2.7)
where d` is the differential current length element, is the I is the current of the element, rˆ is the
unit displacement vector, and r is the distance from the current element.
For a long and thin cylindrical wire, we can solve the magnetic flux density as a function of the
radial distance from the center of the wire. Utilizing symmetry and Ampere’s law, we find that the
magnetic flux is given by,
B(r) =
µI
2pir
rˆ (2.8)
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2.2.2.3 Magnetic Force on a Magnetic Particle
The general expression for the magnetic force (F) on a magnetizable object is given by [91,92],
F = µ0
∫
V
(M · ∇)Hd3r (2.9)
where M is the magnetization of the particle and H is the magnetic field in the absence of the
magnetizable object.
2.2.2.4 Magnetic Force on a Paramagnetic Particle
For a spherical bead of homogeneous magnetizing field is affected by the demagnetization factor (N )
and is given by [91],
M = χH =
χi
1 +Nχi
H (2.10)
where χi is the intrinsic magentic susceptibility. For a spherical particle, N =
1
3 .
The force on a paramagentic particle depends on the magnetic field.
F =
V∆χ
µ0
(B · ∇)B (2.11)
where V is the volume of the paramagnetic particle, and ∆χ is the difference in volume suscep-
tibility between the particle and the environment.
For a cartesisan coordinate system, this expression becomes,
F = (Bx
∂Bx
∂x
+By
∂Bx
∂y
+Bz
∂Bx
∂z
)xˆ+(Bx
∂By
∂x
+By
∂By
∂y
+Bz
∂By
∂z
)yˆ+(Bx
∂Bz
∂x
+By
∂Bz
∂y
+Bz
∂Bz
∂z
)zˆ
(2.12)
For our earlier example of a long, thin cylindrical wire, we can calculate the magnetic force on a
small superparamagnetic particle. We use equations 2.8 and 2.11 to obtain,
F(r) =
−V∆χµI2
4pi2r3
rˆ (2.13)
2.2.2.5 Inter-particle Electrostatic Repulsion
Particle motility is affected by particle surface charge. The surface charge results in an electrostatic
repulsion among particles. This is particularly important when achieving endocytosis of nanoparti-
cles because aggregated particles prevent internalization. Ions in the media solution can reduce the
effect of this repulsion through electrostatic shielding.
The first layer formed on the surface of the particle is a rigid layer of absorbed counterions called
the Stern layer or Hemholtz layer and has a thickness of approximately the diameter of a hydrated
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(b)
Figure 2.39: Electromagnetic simulations are used to optimize various magnetic profiles. Profiles
can be optimized for various trafficking speeds, focusing size, and aggregation locations. Each array
element has a 16-bit bidirectional resolution. Each magnetic profile can be adjusted on a timescale
of ms.
ion [93, 94]. Beyond the Stern layer is a diffuse layer called the Gouy-Chapman layer. The plane
between the interface of the diffuse layer and Stern layer is called the shear plane [94]. The electric
potential between the shear plane and the bulk solution is known as the zeta potential. The thickness
of the extension of the diffuse layer into the bulk solution is determined by the Debye legnth (κ−1)
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and is given by,
κ−1 =
√
r0kBT
2NAe2I
(2.14)
where r is the dielectric constant, 0 is the permittivity of free space, kB is the Boltzmann constant,
T is the absolute temperature, NA is the Avagadro number, e is the elementary charge, and I is the
ionic strength of the electrolyte [94,95].
2.2.2.6 Fluid Dynamics of Nanoparticles and Leukocytes
In order to estimate the velocity of nanoparticles and leukocytes in vitro, it is useful to consider the
Navier-Stoke’s equation for incompressible flow of a homogeneous Newtonian fluid [96],
∂u
∂t
+ (u · ∇)u = −1
ρ
∇p+ γ∇2u + 1
ρ
F (2.15)
where u is the flow velocity, t is time, p is pressure, ρ is density, γ is viscosity, and F is an
external force such as gravity or magnetic force.
The Reynold’s number is a dimensionless ratio of inertial and viscous forces, and is useful in
predicting flow patterns in fluids. At low Reynolds numbers , viscous forces are dominant and
we can treat flow as laminar. At high Reynolds numbers, inertial forces are dominant and flow is
turbulent. The Reynolds number (Re) is given by,
Re =
ρuL
µ
(2.16)
where u is the velocity of the particle, L is the typical length scale of the system, and µ is the
dynamic viscosity.
Assuming a low Reynold’s number (as is the case with nanoparticles or leukocytes), the frictional
force (Ffr) is given by,
Ffr = 6piµRvs (2.17)
where µ is the dynamic viscosity, R is the radius of the particle, and vs is the particle’s settling
viscosity.
2.2.3 Novel Magnetic Trafficking, Proliferation, and Imaging Box
The system consists of a low-cost magnetic manipulation array, controller, coverslip, and 3D-printed
chassis (Fig 1.10). An external magnetic field controller is used to actuate between various magnetic
profiles. The controller is interfaced using a computer for accurate timing of profile changes. Our
magnetic manipulation array is capable of producing fields up to 10 mT and gradients up to 300
mT/m. The coverslip acts as a waterproof and transparent barrier between the electronics and cell
media. An inlet port on the chassis enables the attachment of tubing for providing atmosphere. The
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atmosphere travels from the tubing, into the inlet port, through the structure of the chassis, and out
through distribution ports inside the petri dish (Fig. 2.41). The assembly of the cell box is shown in
Fig. 2.43. As a demonstration of trafficking ability of our cell box, both bead trafficking experiments
and cell trafficking are performed. As a control against nonmagnetic fluid flow, we have manipulated
both THP-1 cell populations (Fig. 2.42b) and superparamagnetic microparticles (Fig. 2.42a) in
the presence of nonmagnetic nanoparticles. The system uses electrical current duty cycling for
temperature control. The total active area of the array is approximately 16 mm2. Electromagnetic
simulations were used to investigate various magnetic profiles for maximizing trafficking speed and
aggregation profiles. The simulations are shown in Fig. 2.39. The fabricated flexible DPMF array
is shown in Fig. 2.40. Each trace has a thickness of approximately140 µm. The pitch and width of
each trace is 0.3 mm. The total active area is 7.3 mm3. The dielectric is composed of a polyimide
substrate. The DPMF array is integrated into the cell box.
Figure 2.40: Fabricated flexible DPMF array.
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(a)
(b)
Figure 2.41: One of the core components of the DPMF device is (a) a 3D printed cell box. The box
is printed from PLA plastic and contains life-support features for magnetically trafficked cells. In
the split view (b), a CO2 inlet port and distribution channels ensure optimal pH of cell media. A
coverslip slot allows for the waterproof attachment of a large coverslip. The interface ensures the
system electronics do not interfere with cell media. The cell box adapts to a standard 100 mm petri
dish and fits on typical inverted microscopes.
2.2.4 SPION-CpG Construct
2.2.4.1 SPION-CpG Synthesis
To perform the in vitro magnetic field influenced cell movement studies, SPION-CpG conjugates
(Fig. 2.44) were prepared from 30 nm SPIONs (Fig. 2.45) [97]. The synthetic protocol was intended
to produce CpG conjugated to PEG with a terminal silyl ether for conjugation to the SPIONs, but
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(a)
(b)
Figure 2.42: Demonstration of magnetic control of magnetic particles and human monocytes (THP-
1). Human monocytes endocytosed magnetic particles and were labeled with green fluorescent
protein (GFP). The first step of the magnetic control is the aggregation of cells and beads. After
aggregation, the cluster is moved to a separate position.
Figure 2.43: Cell box assembly
Mass Spectrometry (MS) analysis (Fig. 2.45) indicated that the reduction of RSSCpG was inefficient
and thus the majority of material used to coat the SPIONs was likely RSSCpG. Nonetheless, it was
clear that a functional coating was achieved as demonstrated by the change in aqueous stability
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of the SPIONs. The as-received SPIONs were coated with oleic acid and thus not miscible with
water, but, following sonication with the CpG-containing material, the SPIONs entered the aqueous
phase. Furthermore, zeta potential measurements showed the resulting SPION-CpG particles to be
negatively charged, consistent with an oligonucleotide coating (Fig. 2.44). Dynamic light scattering
measurements indicated that the SPION-CpG conjugates have a hydrodynamic diameter of 94 5
nm, as compared to 46 2 nm for the free SPIONs (Fig. 2.44). This is likely the result of small
aggregates forming following the coating, as revealed by transmission electron microscopy (TEM,
Fig. 2.44).
Figure 2.44: Synthesis and characterization of the SPION-CpG conjugates. (a) Schematic illustra-
tion of the synthesis of SPION-CpG conjugates. (b) Hydrodynamic diameter and zeta potential
of SPION-CpG conjugates. (c) Transmission electron microscopy image of the SPION-CpG con-
jugates. (d) LIVE/DEAD stain of N9 cells treated with 0.5 mg mL-1 for 12 h. Red = ethidium
homodimer (dead), green = calcein AM (live). (e) NFB activation of RAW-Blue mouse macrophage
reporter cells treated with 0.1 mg mL-1 SPION-CpG (n = 2, 6 replicates each). The average of the
normalized data from two assays is shown.
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2.2.4.2 Microglia SPION-CpG Uptake and Viability
Cell assays indicated that SPION-CpG was both non-cytotoxic and immunostimulatory (Fig. 2.44).
The LIVE/DEAD assay was used to evaluate cell viability of N9 mouse microglia cells after 12 h
of loading at SPION-CpG concentrations up to 0.5 mg mL−1. As shown in Fig. 2.44 and Fig.
2.45 the treated cells exhibited an equivalent level of viability as untreated control cells. In order
to evaluate the immunostimulatory potential of SPION-CpG, an NFκB reporter cell line was used.
Because NFκB activity is increased in response to TLR9 activation by CpG, immune stimulation
by SPION-CpG was expected to cause an increase in NFκB signal within this reporter system.
Indeed, SPION-CpG treatment induced an increase in NFκB activity when compared to untreated
cells (Fig. 2.44). However, the NFκB activity of SPION-CpG was less than an equivalent amount
of free CpG (RSSCpG). This reduction in activity has several possible causes. It is possible that
some CpG was lost during the SPION-CpG synthesis process, thus resulting in lower NFκB activity
after uptake by reporter cells. It is also possible that the immunostimulatory activity of CpG was
partially inhibited by conjugation to SPIONs. Phosphate groups are well-known for their ability to
bind the surface of iron oxide [98,99]. Therefore it is likely that the phosphorothioate backbone of the
CpG oligonucleotide interacted with the surface of the SPIONs, interfering with CpG release or its
binding to TLR9 [100]. Future work will focus on investigating the mechanism of this phenomenon
and further enhancing the immunostimulatory activity of SPION-CpG.
Next, inductively coupled plasma mass spectrometry (ICP-MS) was used to quantify the cellular
uptake of the SPION-CpG by N9 microglia. Briefly, cells were treated with increasing concentrations
(0, 0.01, 0.1, 0.3 and 0.5 mg mL−1) of SPION-CpG conjugates for 12 h, washed thoroughly, digested
with nitric acid, and analyzed using ICP-MS. A dose-dependent increase in iron content above
the normal background level in control cells was observed (Fig. 2.47). For comparison, cells were
also treated with the commercially available Ferumoxytol iron oxide nanoparticles (sold under the
name Feraheme), which are approved for human use by the US Food and Drug Administration.
Ferumoxytol particles are similar in size to the SPIONs used in this study, with an iron core diameter
of 1730 nm [101]. However, even when cells were exposed to a 3x higher concentration of Ferumoxytol
as compared to SPION-CpG, very little uptake of the Ferumoxytol particles was observed. While
there are a number of differences between our SPION-CpG and Ferumoxytol, we speculate that this
increased loading of SPION-CpG was due to the oligonucleotide coating. It has previously been
shown that oligonucleotide coatings lead to enhanced cell uptake mediated by scavenger receptors
[102, 103]. Independent of the mechanism responsible, the enhanced uptake for our SPION-CpG
made this material appealing for use in the magnetic control of microglia.
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Figure 2.45: (a) Transmission electron microscopy image of the SPION. (b) Histogram size distri-
butions obtained by counting approximately 100 particles. (c) LIVE/DEAD staining of untreated
control cells. (d) NFB activity data from two independent assays.
Figure 2.46: SPION-CpG is internalized in N9 cells. Dark-field images of (a) microglia cells alone
and (b) cells loaded with SPION-CpG conjugates (0.5 mg/mL). (c-d) TEM images of loaded cells.
ICP-MS analysis of (e) cells treated with increasing concentrations of SPION-CpG conjugates and
Ferumoxytol. (f) Cell and supernatant fractions at various time points after loading (n=2 with treat-
ments performed in triplicate, data from one experiment is shown). Error bars represent standard
deviations of iron content in replicate wells.
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2.2.4.3 Large Scale Uptake and Distribution Imaging
Further, dark-field microscopy imaging was performed to show the uptake and distribution of the
particles over a relatively large area. N9 cells treated with SPION-CpG conjugates at a concentration
of 0.5 mg mL−1 were assessed using a dark-field microscope. Untreated control cells showed no
uptake (Fig. 2.47), whereas cells treated with SPION-CpG conjugates showed profound uptake of
the SPIONs (Fig. 2.47). TEM imaging was also performed to gather information on the intracellular
distribution of the SPION-CpG conjugates. At low magnification, TEM imaging performed across
various regions of the grid revealed strong uptake of the SPION-CpG conjugates, in agreement with
dark-field microscopy. Higher magnification TEM imaging showed dense aggregates of particles that
were predominantly located in intracellular vesicles (Fig. 2.47). Some particles were observed in the
cytoplasm as well, and no particles were found in the nucleus. Similarly, no uptake was observed in
the untreated control cells (Fig. 2.46).
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Figure 2.47: SPION-CpG is internalized in N9 cells. Dark-field images of (a) microglia cells alone
and (b) cells loaded with SPION-CpG conjugates (0.5 mg/mL). (c-d) TEM images of loaded cells.
ICP-MS analysis of (e) cells treated with increasing concentrations of SPION-CpG conjugates and
Ferumoxytol. (f) Cell and supernatant fractions at various time points after loading (n=2 with treat-
ments performed in triplicate, data from one experiment is shown). Error bars represent standard
deviations of iron content in replicate wells.
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2.2.4.4 Microglia SPION-CpG Exocytosis
After verifying that SPION-CpG was internalized by N9 cells, the exocytosis of these particles was
then investigated. This has important implications in experiments involving magnetically-induced
movement. As a cell exocytoses SPIONs, its responsiveness to magnetic fields will decrease as a
function of the amount of residual intracellular iron. Thus the rate of exocytosis affects the time
period over which the cells can be moved in vitro. In order to track the rate of exocytosis, N9 cells
were loaded and the iron content of both the cells and the cell media was measured at 0, 8, and
24 h after loading. Over a 24 h period, there was no detectable increase in the iron content of the
cell media nor was there a detectable decrease in the iron content of the cell fraction (Fig. 2.47).
Therefore, we concluded that exocytosis of SPION-CpG was negligible in N9 cells over 24 h. The
background iron level in the media at 0 h was presumably residual free SPION-CpG which was
not removed when the loaded cells were washed with PBS two times. Longer time points were not
investigated because 24 h proved sufficient to demonstrate robust in vitro movement.
Figure 2.48: Magnetically induced movement of the cells loaded with SPION-CpG conjugates. (a)
Color images of loaded cells after exposure to magnets of different shapes for 20 h. The concentration
of SPION-CpG used for loading was 0.1 mg/mL. (b-d) are the various controls used for the magnetic
movement experiments; unloaded cells with (c) and without (b) exposure to the rectangular shaped
magnet, and SPION-CpG only without cells (d). (e-f) SEM images of cells after movement. (g-h)
Brightfield and fluorescent images of LIVE/DEAD-stained cells after movement.
2.2.4.5 Demonstration of Magnetic Response using Permanent Magnet
As a simple test to evaluate if SPION-CpG-loaded microglia could be controlled with an external
magnetic field, three different shaped magnets were placed underneath glass bottom culture dishes
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containing adherent N9 cells loaded with SPION-CpG. After 20 h, the media was aspirated, the
plates were stained with Prussian blue, and photographs were taken to demonstrate the shape-
dependent localization of the loaded cells (Fig. 2.48). Additionally, this magnetically controlled
cell movement was correlated with the dose of SPION-CpG given to the cells, with higher loadings
leading to more pronounced accumulation at the magnet (Fig. 2.49). As controls, we also imaged
SPION-CpG particles only with magnet exposure, untreated cells with magnetic exposure and cells
loaded with SPION-CpG that were not exposed to any magnets. The SPION-CpG only control
shows almost no adherence of the particles, such that following staining and washing, very little
material remained in the dish (Fig. 2.48). Neither empty cells that were exposed to the magnet
nor loaded cells not exposed to the magnet migrated in vitro, confirming that the shape-dependent
localization of the loaded cells was magnetically controlled (Fig. 2.48). In order to more closely
monitor the magnetically induced migration of the cells, higher magnification images were recorded
for loaded cells after 0, 2, 4, and 20 h of magnet exposure (Fig. 2.51). Accumulation of the loaded
cells at the edge of the magnet where the magnetic field gradient was largest was observed by 4 h
and increased until 20 h. Collectively, these controls demonstrate that the accumulation at the edge
of the magnet was due to SPION-loaded cells moving in response to the magnetic field.
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Figure 2.49: Magnetically induced movement of the cells loaded with increasing concentrations of
SPION-CpG. Color images of the cells placed underneath the magnet of different shape (shape
indicated in the image) for 20 h, taken using an iPhone camera. Increasing concentration of SPION-
CpG used were 0.1, 0.3, and 0.5 mg/mL for (a), (b), and (c), respectively.
2.2.4.6 Cell Viability and Morphology After Magnetic Trafficking
In order to verify that magnetically-induced movement was nontoxic, the migrated cells were ex-
amined for changes in viability and cell morphology. Because the migrated cells comprise only a
small percentage of the total cell population of the dish, assays that analyze the bulk cell popula-
tion would not be able to detect changes in the migrated cell population due to a high background
signal from the non-migrated cells. Furthermore, there is no good way to separate the migrated and
non-migrated cell populations prior to analysis. Therefore, analysis of the migrated population was
performed using imaging-based techniques. Imaging-based techniques allow the spatial information
from the cells to be preserved during the analysis, enabling quick identification of migrated and
non-migrated populations.
Viability and cell morphology were examined via the LIVE/DEAD assay and SEM, respectively.
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After loaded cells were exposed to the magnet for 20 h and clear migration was observed, the cells
in the dish were stained with calcein AM and ethidium homodimer, fixed, and then fluorescently
imaged to assess viability. After fluorescence imaging, the same region of cells was imaged by SEM.
No decrease in cell viability was detected for migrated cells nor were any gross abnormalities in cell
morphology observed (Fig. 2.48, 2.49).
2.2.4.7 Magnetic-field Induced Qualitative Cell movement in vitro by bright-field mi-
croscopy
The movement of cells loaded with SPION-CpG conjugates is primarily determined by the external
magnetic field profile and strength, the hydrodynamic properties of the cell in its environment, and
the effectiveness of SPION uptake by the cells. An important evaluation of cell motility is the
quantification of movement velocity. Therefore, in order to analyze the movement velocity of cells,
an innovative imaging, incubation, and magnetic manipulation apparatus was designed (Fig. 2.43).
The apparatus consists of our custom cell box fitted onto a standard sized petri dish. N9 cells
were plated onto the coverslip portion of the cell box and then loaded with SPION-CpG. After cell
loading, the entire box assembly was then inverted into a petri dish containing culture medium. For
time-lapse imaging, the cell box and petri dish were placed onto the stage of an inverted microscope
equipped with incubation capabilities. A ceramic permanent magnet was then placed on the opposite
side of the coverslip to which the cells were attached.
Figure 2.50: Histograms of (a) horizontal and (b) vertical cell velocities in motility experiment.
Magnetized cells were imaged over a period of 12 h under the exposure of a magnetic field. The
external magnet was placed in the positive vertical position to the cells. Velocities were calculated
by extracting the change in cell position from one frame to the next. The average velocity was
0.2±3.72 µm/min and the vertical direction and 0.03±1.69 µm/min in the horizontal direction.
During magnet exposure, the cells were imaged at 2 frames min−1 for a period of 20 h. Cell
positions were extracted using an image processing algorithm [104]. The distribution of cell velocities
in the vertical direction (toward the magnet) and horizontal direction is shown in Fig. 2.50. The
histograms in Fig. 2.50 show that the cell movement in the horizontal direction was symmetrical,
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while cell movement in the vertical direction was skewed toward the externally-applied magnetic
field. In some cases cells migrated toward the magnet at velocities exceeding 30 µm min−1.
Figure 2.51: Time-lapse of cell movement
2.2.5 Conclusion
Immunotherapy is an attractive treatment strategy for many diseases, including cancer [105]. Gen-
erally, this strategy involves stimulating the immune system such that it recognizes the diseased
cells as foreign and eliminates them. A wide variety of agents, ranging from antibodies, to engi-
neered immune cells, to potent adjuvants have been used to induce immune system stimulation.
Immunotherapy would be greatly enhanced as a treatment strategy if the location of the immune
cells both during and after stimulation could be controlled. For the case of cancer immunotherapy,
it could be of great benefit to localize the immune cells receiving stimulation to the tumor to pro-
mote antigen recognition specifically for cancer cells. Furthermore, the immune response could be
enhanced by maintaining a population of activated immune cells at the primary tumor site and/or
improving the trafficking of activated immune cells to distant foci of disease.
We have been pursuing the use of oligodeoxynucleotides that contain an unmethylated CpG motif
(CpG) as immune stimulants for the treatment of glioblastoma. CpG is known to be immunostimu-
latory by activating toll like receptor-9 (TLR9) which is expressed by normal and glioma-associated
human microglia and macrophages [106–109]. SPION-CpG conjugates were non-toxic to N9 mi-
croglia cells and were efficiently internalized into endosomal compartments. This enabled magnetic
control over microglia motility in vitro. This work establishes the possibility of using a nanoparticle
to both stimulate immune cells and to control their trafficking.
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To magnetically manipulate in a controlled and dynamically actuated profile, a custom 3D printed
cell box is introduced. The cell box also enables the simultaneous live imaging and incubation of
magnetic particles or cells. The measurement setup is used to manipulate magnetically loaded THP-
1 cell. Future experiments will investigate the optimal coating for the SPIONs to further enhance
immune cell activation and developing volumetric magnetic manipulation chamber for in vivo cell
trafficking.
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Chapter 3
Other Works
3.1 Transistor Scaling and Variation
Transistor scaling has enabled the exponential growth of the number of CMOS transistors on single
die, as predicted by Moore’s law [110]. The ability to scale transistors has ushered huge performance
gains in computing. This is the result of favorable scaling in transistor parameters such as gate
capacitance, switching speed, and propagation delay. However, this scaling has also increased process
and dynamic variations of CMOS transistors. For example, random dopant fluctuations are a result
of the decreasing number of dopant atoms in a transistor channel and is the major contributor to
device mismatch (Fig. 3.1) [5]. As transistor channel length scales smaller, the variabilty in the
placement and presence or absence of a few dopant atoms leads to significant transistor performance
variation. These variations, along with environmental variations, can be especially detrimental to RF
transmitters and receivers. Various techniques are used to mitigates the effects of process variation.
Figure 3.1: Average number of dopant atoms int he channel as a function of technolgoy node [5].
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3.1.1 Self-Healing Circuits
A fundamentally different design methodology is required to ensure robust IC performance as tran-
sistor scaling and variability increases. Recently, a self-healing design methodology was proposed
utilizing a closed loop healing algorithm [111]. We demonstrate a continuation of this work with two
representative circuit architectures: a mm-wave transmitter and a high output power PA [112,113].
3.2 A Self-Healing mm-Wave Power-Mixer in 32 nm CMOS
3.2.1 Introduction
A surge of demand for high-speed communication systems has developed due to the increasing perva-
siveness of wireless technology and devices. An important advancement in satisfying the bandwidth
requirements of these devices is the development of millimeter-wave (mm-wave) transmitters and
receivers able to operate above and beyond 30 GHz. Additionally, non-constant envelope modulation
schemes such as quadrature amplitude modulation (QAM) are necessary to fully utilize the avail-
able bandwidth in this spectrum. In order to transmit symbols at differing amplitudes, the power
amplifiers (PAs) in these communication systems must be operated in significant back-off. Even in
constant envelope modulation schemes, the PA may still be operated in back-off to improve linear-
ity. Unfortunately, the backoff efficiency of PAs are usually significantly degraded when operating
in backoff. Several class-A PAs have nearly a 25% reduction in efficiency when operating at 6-dB in
backoff [114–116]. High energy efficiency is crucial for extending device battery life and improving
communication range.
In addition to high energy efficiency, mm-wave PAs require high output power for improving
device range and communication reliability. Switching PAs have been developed to achieve high
efficiencies and high output power [117,118], but lack the ability to perform non constant amplitude
modulation. Spatial power combining has also been used to achieve high output power by digitally
switching a set of power DACs and patch antennas while operating each at high efficiency [117].
However, this scheme requires a large area overhead due to multiple chips and radiating elements.
One method of efficient on-chip power combining is the distributed active transformer (DAT) [119].
DAT relies on transformer-based power combining of multiple differential power stages while pro-
viding easy supply connections through virtual shorts along the transformer. The transformer also
provides an impedance transformation for matching the power elements to the antenna. However,
previous architectures have been unable to simultaneously achieve high frequency operation with low
area overhead, high backoff efficiency, and high output power, while also being capable of generating
complex modulation schemes at high data rates [114,120–122]. We developed a 19.1 dBm segmented
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power-mixer based multi-Gb/s mm-wave transmitter in 32 nm SOI CMOS (Fig. 3.2) [112, 113] 1.
Each power-mixer is operated near saturation to maximize efficiency. To achieve backoff operation,
various segments of the power mixer can be turned ON or OFF depending on power requirements.
The DAT achieves a 4-to-1 combining while having two easily accessible supply taps. Each power
mixer (Fig. 3.3) consists of a Gilbert cell switched-transconductor mixer [123]. A polar modulation
scheme is used to supply phase information through the local oscillator (LO) signal and amplitude
information is provided by the baseband (BB) signal. A single-ended off-chip LO signal is converted
to a differentail signal using an on-chip transformer and routed to each of the lower transistors in the
power-mixer. The phase of the LO signal is modulated using an LO drive network based on invert-
ers. BB signals can be operated in either a digital mode (each either ON or OFF), or a fully analog
mode. As transistor scaling shrinks the size of transistors, process variations decrease the reliability
of transceivers. Moreover, environmental variations can have a detrimental impact on transceivers.
For example, the impedance of an antenna in a cellular device can vary due the proximity of a
hand. To adapt to these changes, we have designed self-healing capabilities in the system (Fig. 3.4
and 3.5). The transmitter is able to “sense” its performance. If performance is suboptimal, a set
of actuators adjusts the operation of the transmitter to recover optimal performance. An on-chip
healing microprocessor acts as the “brain” of the self-healing circuitry and automatically “heals” the
performance of the chip. Healing sequences can be adjusted for faster coarse optimization, or finer
optimization. Sensors consist of couplers with RF power sensing, phase detection, and DC current
sensing. Actuators consist of a phase rotator and fine control of transistor biases. The layout of this
design is shown in Fig. 3.6.
Figure 3.2: Die photograph of a 19.1 dBm segmented power-mixer based multi-Gb/s mm-wave
transmitter designed in 32 nm SOI CMOS.
1This project would not have been possible without the gracious help of Kaushik Sengupta and Kaushik Dasgupta.
The majority of contribution is in sensors, actuators, and self-healing infrastructure.
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Figure 3.3: Transistor level schematic of power mixer stage.
Figure 3.4: Overall architecture of the segmented power mixer-based transmitter with self-healing
infrastructure.
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Figure 3.5: Input balun, drivers, DAT, and feeds.
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Figure 3.6: Die photo of the segmented power mixer-based transmitter with self-healing infrastruc-
ture. The size of the chip is approximately 2 x 2 mm.
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3.2.1.1 Digital Backbone
The core of the digital self-healing algorithm is the on-chip controller (Fig. 3.4 and 3.5). The
controller is composed of an open source 8086 microprocessor and SRAM module was ported and
synthesized by Ben Parker of IBM. The microprocessor interfaces with our custom designed register
widget (Fig. 3.8). The microprocessor, SRAM, and register widget contain a high-speed algorithm
that can detect the performance or symbol accuracy of the transmitter and compensate for process
or environmental variations. A hard-wired optimization algorithm or a custom program can be
loaded onto the microprocessor can initiate healing. The register widget inputs sensor information
through an ADC. An internal state machine is used to read data from a successive approximation
ADC (SARADC) and outputs actuation states through various DACs. The algorithm features an
on-chip autonomous mode and an optional off-chip mode (Fig. 3.7).
Figure 3.7: Optional off chip self-healing mode.
Measured results for actuation states on the current consumption of the power mixer are shown
in Fig. 3.9. To test the microprocessor’s functionality, we wanted tune the bias points of transistors
in the Gilbert cell of the power mixer and monitor the change in current consumption. In the first
test, we programmed DAC settings that interface to each tail transistor in the set of 4 Power Mixers.
Each actuator is associated with a separate DAC. We programmed half the range of our DACs in
the tail transistor while biasing the middle transistor at 0.6V. The saturated current consumption
is consistent with our simulated results. In another test, we varied the bias settings in the middle
transistor of each of our 4 Power Mixers.
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Figure 3.8: Block level diagram of self-healing infrastructure.
(a)
(b)
Figure 3.9: Measured results for DAC control of actuators on the power mixer (a) tail transistors
and (b) middle transistors.
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3.2.1.2 Symbol Healing
Various sensors and actuators enable symbol healing in the transmitter 3.10. A desired symbol
requires accurate phase and amplitude. Phase adjustment is provided to the LO signal through
a phase rotator. The amplitude of constellations by biases provided to the power mixers as well
as power mixer drivers. The amplitude of the constellation is sensed by the RF power sensor and
communicated to the digital core. The phase of the constellation is determined through a phase
detector.
Figure 3.10: A desired constellation requires accurate phase and amplitude. A differential LO signal
will pass through a phase rotator as our actuator for phase healing. The amplitude of constellation is
adjusted by biases provided to power mixers as well as biases to power mixer drivers. The amplitude
of the constellation is sensed by the RF power sensor and communicated to the digital core. The
phase of the constellation is determined through a phase detector.
3.2.1.3 20dB Coupler
A pair of 20dB couplers provide information on transmitted and reflected power (Fig. 3.11). Less
than 1% of output power is consumed. A total of 4-RF power sensors are placed at differential
coupled and isolated ports to detect the amplitude of forward and reflected waves. These provide a
bearing on output power and impedance mismatch. The coupling and isolation are shown in Fig.
3.12. The S parameters of the input and output are shown in Fig. 3.13. The couplers have no
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discernible effect on signal lines. The layout of the coupler is shown in Fig. 3.14.
Figure 3.11: RF coupler design for monitoring transmitter ouput and reflected power.
Figure 3.12: Simulated coupling and isolation of RF coupler.
3.2.1.4 RF Power Sensor
The RF voltage sensor (Fig. 3.16) is used to measure the amplitude of a sinusoidal waveform. When
combined with the properly terminated 20dB coupled line, the voltage sensor acts as a power sensor.
The input transistor is biased near cut-off and acts as a rectifier. Subsequent stages filter and amplify
the input amplitude. The input bias (Vbias) can be used to trade off sensitivity for dynamic range.
To measure the performance of the RF power sensor, test chips are fabricated and measured with a
probe output of a calibrated signal generator. The supply biasing is provided using a power supply
and the output was measured with a multimeter. The input power was then plotted with respect
to the output voltage. The output of two fabricated test chips are shown in Fig. 3.17. In the full
transmitter, the output of the RF sensor is provided to the register widget through the SARADC.
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Figure 3.13: S paramters of the couplers show little impact on output traces.
Figure 3.14: RF coupler layout.
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Figure 3.15: RF power sensor test setup. A signal generator provides power at various levels to a
test chip through probes. The output of the sensor is measured using a multimeter.
Figure 3.16: The RF power sensor’s input consists of a transistor biased at cut-off. The input
transistor rectifies the input waveform. After filtering and current mirror amplification, the output
is provided to the self-healing controller. The bias of the input transistor can be varied to trade of
sensitivity for dynamic range.
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Figure 3.17: The output of two measured chips is shown. The output voltage is correlated with the
amplitude of the input signal.
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3.2.1.5 DC Current Sensor
An important datum is the DC current consumption of the DAT and power mixers. In particular,
the power consumption allows us to determine the efficiency of the transmitter. This is useful in
determining which of many states are most optimal in operation. For example, the self-healing
infrastructure could toggle between states and choose one which results in minimal DC power con-
sumption. The sensor provides a supply connection for the PA stage (Fig. 3.18). In order to
minimize power dissipation, a 1/100X mirroring ratio is used to monitor PA current. In addition, an
array of 104 12µm-width transistors are used to minimize voltage drop across the supply transistor.
A voltage reference is used to bias the supply transistor gate and ensure only 10 mV of voltage drop
across the drain and source. The response from several measured test chips is shown in Fig. 3.20
and 3.19.
Figure 3.18: Schematic of the DC sensor.
Figure 3.19: Test setup for measuring DC sensor response
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Figure 3.20: Measurement results of DC sensor. The DC sensor was tested under nominal biasing
conditions providing a 1.7V Vdd to the power mixer. Note that the DC sensor is linear within the
operating range of the power mixer (0-100 mA). Standard deviations from multiple chips are also
depicted in the figure showing robustness of the sensor.
3.2.1.6 Phase Rotator
In order to properly heal an improperly generated symbol, both phase and amplitude adjustment
capabilities must exist. The phase of the output symbol is adjusted by actuating the phase encoding
of the LO differential signal. The phase is adjusted using a phase rotator, as seen in Fig. 3.21.
This enables high speed phase rotation without the challenges associated with off-chip high-speed
modulation. I-Q signals are added with variable levels to generate differing phases. The output of
the phase rotator is directly connected to the input of the driver stages. The total size of the layout
is 15 x 30 µm (Fig. 3.22).
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Figure 3.21: Phase rotator to aid in symbol healing. I-Q signals are generated on chip using a
transmission line. The weights of I-Q signals are adjusted by adjusting the Ctrl IP, Ctrl IN, Ctrl QP,
and Ctrl QN signals using on-chip power DACs.
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Figure 3.22: The layout of the phase rotator has a total size of 15 x 30 µm.
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3.2.1.7 Phase Detection
In order to properly adjust phase, symbol phase mismatch must first be determined (Fig. 3.10).
The phase of the power mixer output is sensed using a phase detector (Fig. 3.23. First, the output
of the transmitter is mixed with the chip’s LO signal. The signal is transmitted through a voltage
buffer and low pass filter to generate a DC signal corresponding to the phase offset. The output of
the phase detector versus relative phase to the LO is shown in Fig. 3.25). The layout of the phase
detector is shown in Fig. 3.24. The phase detector has a minimal power consumption of less than 1
mW.
Figure 3.23: The phase detector consists of a transistor mixer of properly terminated, single-ended,
60 GHz LO and RF signals. The DC signal is buffered through a unity feedback op-amp, and filtered
through a low-pass filter. The output DC voltage corresponds to the phase offset of the output of the
power mixer with the LO. The output is recorded through an ADC and recorded by the self-healing
infrastructure.
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Figure 3.24: Phase detector layout. The total size of the phase detector is approximately 60 x 50
µm.
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Figure 3.25: Response of phase detector to phase offset. The phase offset is a relative offset between
the input of the phase detector and the LO signal.
3.2.2 Variation Resistant Phase Detection Based on Min/Max Algorithm
One important requirement to self-healing infrastructure is that sensors and actuators must them-
selves be robust enough to handle process variation. The output of the phase detector is simulated
in a Monte Carlo simulation across multiple process variation corners (Fig. 3.26). As can be seen,
a single output voltage level could correspond to a slew of phase offsets. To mitigate the effect of
process variation on the phase detector, a min/max algorithm is used as part of the self-healing
procedure. To properly identify the phase response, the phase rotator as actuated over a full 360◦
rotation. The maximum and minimum output voltages of the phase detector are recorded. This
relaxes the requirement of requiring a high number of storage bits, sensing space, and digital pro-
cessing while adapting for process variation and mismatch. A binary search can be used to decrease
heal time. Using the max/min values, a cosine is determined for the phase response of the phase
detector. A comparison between predicted phase response and simulated phase response is shown
in Fig. 3.27. Using this method, we were able to achieve a standard deviation of approximately 2◦
in predicted phase variation (Fig. 3.28). An alternative full cosine fit using all values can be used
to further improve the predicted accuracy.
94
Figure 3.26: Monte Carlo simulation of phase detector output over process corners. This figure
shows how process variation could potentially degrade the functionality of the phase detector. The
variation is compensated for through a min/max algorithm. A total of 100 iterations were simulated.
3.2.3 Conclusion
We have developed a compact, broad-band, and efficient transmitter based on a dual-primary-based
DAT design [112,113]. The transmitter is capable of generating a saturated output power of 19.1 dBm
at 51 GHz. The design uses segmented power mixers to enable non-constant envelope modulation
at high speeds with high backoff efficiency. We show high speed modulations using ASK, 3-ASK,
BPSK, QPSK, and 16-QAM. We have also designed a version of this transmitter with self-healing
infrastructure. This enables the transmitter to sense its own performance and tune actuators to
optimize performance and reliability.
3.3 A Self-Healing High Power Amplifier in 32nm CMOS
3.3.1 Introduction
A stacked transistor topology can be used to take advantage of an SOI process (Fig. 3.29) 2. A
total of 5 devices can be reliably stacked before buried-oxide (BOX) breakdown. As the number of
stacks increases, the maximum supply voltage and output power increases. Additionally, the output
2This project would not have been possible without the extremely gracious help of Steve Bowers, Kaushik Dasgupta,
and Amir Safaripour. The majority of contribution is in sensors, actuators, and self-healing infrastructure.
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Figure 3.27: Comparison between predicted phase response using the min/max algorithm and sim-
ulated response. The min/max algorithm uses only the minimum and maximum output voltages of
the phase detector to predict the outputs to other phase offsets. A full cosine fit of several values
can be used to further enhance accuracy.
impedance can also be scaled. Plots of output power and impedance scaling are shown in Fig. 3.30.
Drain voltage and current scaling are shown in Fig. 3.31. The layout of the architecture is shown
in Fig. 3.32.
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(a)
(b)
Figure 3.28: Monte-carlo simulations of phase recovery for (a) 45◦ and (b) 90◦.
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Figure 3.29: Schematic of PA transistor stacking. The drain-source breakdown is 1.4V.
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(a)
(b)
Figure 3.30: (a) Output power scaling versus transistor stack count. (b) Phase difference between
voltage and current at the output.
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3.3.2 Self-Healing Infrastructure
The self-healing infrastructure consits of 5 main blocks: scan chain, controller, SARADC Hand-
shaking module, SARADC, a output DACs (Figure 3.33). The infrastructure interfaces with bias
actuators and power sensors to adjust for a particular output power/amplitude setting. The on
chip algorithm optimizes performance by searching thorugh a bias search space. A flowchart of the
output power and optimization algorithm is shown in Fig. 3.34. The on-chip system features an
adjustment knob that allows for a trade-off between search space size and healing speed. The infras-
tructure aso allows for complete external override for fail-safe. Custom actuator DACs are designed
to prevent breakdown biasing. An RF sensor with coupler is designed to measure output power. The
infrastructure was designed through custom synthesized digital logic from custom designed standard
cells (Fig. 3.35). The layout of the digital block is shown in Fig. 3.36.
Figure 3.31: Drain voltage scaling and drain current as a funciton of stacking.
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Figure 3.32: Layout of high power PA using transistor stacking.
Figure 3.33: Block diagram of self-healing infrastructure.
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Figure 3.34: Output power and efficiency optimization algorithm.
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Figure 3.35: An example of a custom designed standard cell. This particular cell is a 2-input AND
gate.
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Figure 3.36: Demonstration of custom synthesized digital infrastructure from custom designed digital
standard cells.
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Chapter 4
Appendix
4.1 Surface Chemistry: Aqueous/Organic Solvent Deposi-
tion of TESUD
4.1.1 Motivation
• Establish capability to perform silane surface chemistry on silicon nitride surfaces.
• Perform a functional test of amine-conjugated DNA oligo binding to aldehyde functionalized
substrates, including glass and silicon nitride surfaces.
This protocol is taken and modified from the following sources: Hermanson, Greg T., Bioconju-
gate Techniques (2008), Coupling Agents by Gelest Inc., (2006), and Wu et al., Biosensors and
Bioelectronics (2006).
Silicon nitride coated wafers were purchased from University Wafer (150 mm N/Ph (100) 1-20
ohm-cm SSP 650µm with 100nm of nitride). One SiN wafer was scored and cracked into five 3 x 1
sized pieces for this experiment.
4.1.2 Surface Cleaning
1. Rinse the substrates sequentially with acetone, ethanol, and then Millipore DI water. Do not
let the surface dry between rinses.
2. Submerge the substrate in the sonicator (filled with water as the medium) for about 1 min.
3. Dry substrate by blowing clean nitrogen gas over the surface.
4. Subject slides to oxygen plasma cleaning for 2.5 min (gas pressure = 0.3 torr, power = 100
W).
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4.1.3 Surface Reaction
1. Prepare a solution containing 95% ethanol-5% water solution (v/v) and adjust the pH to
4.5-5.5 with glacial acetic acid.
2. Dissolve triethoxysilyludecanal (TESUD) in the acidic water/ethanol solution with stirring to
a final concentration of 2% (v/v). Allow hydrolysis to occur for 5 min at room temperature
to form reactive silanols.
3. Dip glass substrates into silane solution and incubate for 2 h.
4. Wash the glass slides three times with ethanol or the water/ethanol mixture to remove excess
silane compound.
5. Cure the silane-modified glass slide by incubation at 110◦C for 30 min.
4.2 DNA Conjugation: Immobilization of Thiol-functionalized
DNA to Amino-coated Glass Substrates
4.2.1 Motivation
• Establish capability to perform surface chemistry on glass slides.
• Demonstrate protocol for immobilizing thiol-modified DNA oligos to an amino-functionalized
glass surface
This protocol is modified from Wu et al., Biosensors and Bioelectronics (2006).
4.2.2 Surface Reaction
1. Dissolve sulfo-SMCC at a concentration of 0.2 mg/mL in 50mM sodium borate buffer (pH=7.5).
Incubate amino-modified glass slides in solution for 2 h. Room temp.
2. Rinse 1x with fresh sodium borate buffer, then 3x with ddH2O.
3. Measure contact angle of the SMCC modified surface and compare to a non-modified surface.
4.2.3 DNA Immobilization
1. Treat oligo with 10mM DTT for 15 min.
2. Pass oligo + DTT through a G-25 spin column to remove the DTT.
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3. Spot 1mL of 3x SSC containing oligomer (use range of 1000, 500, 250, and 100 ng/mL DNA)
on glass slide. Place slides on the rack in an empty pipette tip box, fill bottom of box with
40mL of 3x SSC and incubate for 6 h at room temperature.
4. Immerse slides in a solution of 50mM 2-mercaptoethanol in 50mM sodium phosphate buffer
(pH=6.6) for 30 min to block unreacted surface-bound maleimide groups.
5. Rinse slides 3x with 150mM phosphate buffer saline (PBS), then 3x with ddH2O.
6. Immediately place slides in 4x SSC with 0.1 wt% SDS solution, heat to 50◦C for 30 min to
remove non-specifically bound DNA probes. Rinse with ddH2O 3x and dry by centrifugation.
4.2.4 Hybridization
1. Prepare hybridization solution (50mL total volume): 4x SSC, 0.2 mg/mL BSA, 100 mg/mL
salmon sperm DNA, 0.1% SDS, and 1.5mg of Cy3-labelled DNA. For negative control, include
only 4x SSC. [Or, for 50 mL total volume add the following: 32.5 mL 5x SSC, 7.5mL dH20,
7.5 mL Cy3-labelled DNA, 1mL of 1% BSA stock (in 3x SSC), 0.5mL salmon DNA, and 1 mL
of 10% SDS.]
2. Heat hybridization solution to 100◦C for 2 min. Cool in 30◦C water bath for 30 s.
3. Place 45 mL hybridization solution onto slide, and cover with coverslip. Incubate overnight
( 12 h) at 55◦C in a pipette tip box (lower part filled with 40mL of 3x SSC and slide placed
over perforated surface). Protect from light.
4. Wash in 250 mL of 0.5x SSC with 0.01% SDS on orbital shaker for 2 min.
5. Wash in 250 mL of 0.5x SSC on shaker for 3 min.
6. Wash in 250 mL of 0.1x SSC on shaker for 3 min. Repeat this wash two additional times, but
for 1 min.
7. Wash in 250 mL of 0.01x SSC for 5 seconds, and dry immediately (by compressed air).
8. Scan slide with a fluorescence slide scanner.
4.3 DNA Conjugation: Immobilization of Amine-functionalized
DNA to Aldehyde-Coated Glass Substrates
4.3.1 Motivation
• Improve the efficiency of amine-conjugated DNA binding to aldehyde slides.
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• Include a bake step after printing to help stabilize the Schiff base bond.
• Include a hybridization step to visualize DNA bound to the surface, since NaBH4 treatment
destroys the Cy3 fluorophore.
This protocol is modified from ArrayIt’s website [124].
4.3.2 DNA Immobilization
1. Dilute 100 mM DNA oligo into 1x printing buffer (ArrayIt).
2. Print DNA onto aldehyde slides (ArrayIt or VWR) with the humidity set at 60%.
3. Bake the slides for 30 min at 80◦.
4. Allow the slides to set overnight at room temperature and humidity < 30%.
5. Image slides a fluorescence scanner.
6. Rinse the slides in 0.1% SDS twice (2 min) and once in water (2 min). Finally, rinse in water
for 2 min with vigorous agitation.
7. Reduce for 5 min with gentle mixing in 500 mL sodium borohydride reducing solution (dissolve
1.5 g NaBH4 in 350 mL phosphate buffered saline (PBS) and add 150 mL 100% ethanol after
the NaBH4 dissolves to improve reducing efficiency).
8. Rinse 2 times for 1 min each in 500 mL dH2O, rinse 2 times for 1 min each in 500 mL 0.1%
SDS 3x with 150 mM phosphate buffer saline (PBS), and then rinse 3x with ddH2O.
9. Image slides with a fluorescence scanner.
4.3.3 Hybridization
1. Prepare hybridization solution (50mL total volume): 5x SSC, 0.2 mg/mL BSA, 0.1% SDS,
and 1.5 mg of Cy3-labelled DNA. (For 500 mL total volume add the following: 100 mL 20x
SSC, 384 mL dH20, 12mL Cy3-labelled DNA, 8 mL of 10 mg/mL BSA stock, and 4 mL of
10% SDS).
2. Heat hybridization solution to 61◦C for 2 min.
3. Place 50 mL hybridization solution onto slide, and cover with coverslip.
4. Incubate overnight ( 12 h) at 55◦C in a pipette tip box (lower part filled with 40mL of 3x
SSC and slide placed over perforated surface). Protect from light.
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5. Wash in 250 mL of 0.5x SSC with 0.01% SDS on orbital shaker for 2 min.
6. Wash in 250 mL of 0.5x SSC on shaker for 3 min.
7. Wash in 250 mL of 0.1x SSC on shaker for 3 min. Repeat this wash two additional times, but
for 1 min.
8. Wash in 250 mL of 0.01x SSC for 5 seconds, and dry immediately (by compressed air).
9. Scan slide with a fluorescence scanner.
4.4 Detailed DNA Functionalization of IC
4.4.1 Materials
Hybridization Buffer
Target DNA at desired concentration
1X PBS, 1 mg/mL BSA, 5 nM EDTA
0.1% Tween-20
0.1 mg/mL salmon sperm DNA
Bead Binding and Washing Buffer
5 mM Tris-HCl pH 7.5
0.5 mM EDTA
1M NaCl
Stringent Wash Buffer 1
Stringent Wash Buffer 2
4.4.2 Protocol
1. Rinse 3x with 200 µL of hybridization buffer, do not allow to dry.
2. Let the last rinse incubate for 15 min.
3. While incubation occurs, prepare DNA hybridization buffer
4. Add 200µL of hybridization mix and incubate for 30 min.
5. When incubation occurs, prepare bead solution.
(a) Vortex Dynal Bead vial for 30 sec.
(b) 100 µL of bead solution=10 µL of strep mag bangs beads + 90 µL of 1x Binding Washing
Buffer
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(c) Vortex for 30 sec, then magnetically separate.
(d) Aspirate out solution.
(e) Repeat previous 3 steps two additional times.
6. Add 250 µL of wash buffer 1 to well, wait 2.5 min
(a) 1mL of wash buffer = 900 µL of water + 100 µL of Arrayit 10x stock.
7. Repeat previous step.
8. Rinse with 200-300µL of Binding and Washing buffer 3-5 times.
9. Add 100µL of bead solution to well and sit for 20 min.
10. Place a piece of saran wrap over the well.
11. Cut off the cap of a micro-centrifuge tube and place it on the well.
12. Flip over the slide. Make sure there are no air bubbles in the well. Wait at least 15 min for
the beads to settle to the cap.
13. Without flipping over, remove cap and pour out solution.
4.5 Experimental Details of SPION-CpG Construct Analysis
Ultrasonication was performed using a QSONICA Sonicator Q700 (QSONICA, Newtown, CT, USA)
equipped with a cup horn cooled with running water from the sink. Super paramagnetic iron oxide
nanoparticles (30 nm, catalogue #SOR-30) were purchased from Ocean Nanotech, Springdale, AR,
USA. Silane-PEG-NH2 (MW = 2000, Catalogue #PG2-AMSL-2k) was purchased from NANOCS.
Dithiotheritol (DTT) was purchased from VWR. Fully phosphorothioated CpG oligonucleotides
bearing a terminal dithiol (5-HO-C6-SS-C6- T*A*A*A*C*G*T *T*A*T*A*A *C*G*T*T*A*T*G
*A*C*G*T*C*A*T* -3) (RSS-CpG) was provided by the DNA/RNA Core Facility at Beckman Re-
search Institute at City of Hope. Sulfosuccinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate
(Sulfo-LC-SPDP) was purchased from ProteoChem (catalogue #c1118). Illustra NAP-25 columns
(catalogue #17-0852-01) were purchased from GE Healthcare. All other chemicals and reagents
were from standard commercial sources. N9 cells were cultured in Dulbecco’s Modified Eagle
Medium (with high glucose, L-glutamine, sodium pyruvate) supplemented with 10% fetal bovine
serum (FBS), HEPES (0.01 M), penicillin (100 U mL−1), and streptomycin (100 µg mL−1) and
incubated at 37 ◦C in a humidified 5% CO2 atmosphere. For movement experiments, cells were
cultured in glassbottom dishes (MatTek Corporation, catalogue # P35G-0-14-C). Coverslip removal
fluid (catalogue # P DCF OS 30) was obtained from MatTek.
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4.5.1 SPION-CpG Synthesis
Silane-PEG-NH2 (29 eq., 17 mM) and Sulfo-LC-SPDP (17 eq., 10 mM) were dissolved in deionized
water and stirred for 2 h at room temperature. Meanwhile, RSS-CpG (1 eq.) was dissolved in
deionized water containing at least 2.5 mM DTT and stirred for 2 h at room temperature. DTT-
treated RSS-CpG was then passed through a nap-25 column (GE Healthcare) in order to remove
excess DTT. The CpG solution was then added to the silane-PEG-NH2-containing reaction and
heated in a 60◦C oil bath for at least 2 h. After 2 h, the reaction was isopropanol-precipitated,
dialyzed against deionized water using a < 3.5 kD MWCO membrane, and lyophilized.
The lyophilized material was dissolved in deionized water and diluted to an effective CpG con-
centration of 2 mg mL−1 based on UV absorbance at 260 nm (RSSCpG ε260nm = 261,900 L mol−1
cm−1). Then SPIONs (25 mg mL−1 in chloroform) were combined with the product stock solution
in a 1:1 mass ratio (SPION:CpG). The mixture was rotated for 10 min and distributed into 1.5
mL microcentrifuge tubes with < 1 mL in each. To disperse the SPIONs, the sample tubes were
ultrasonicated for a process time of 4 h (80 amplitude, 15 s on, 15 s off). The SPION-CpG con-
jugates were then dialyzed (100 kD MWCO) against deionized water. After dialysis, the samples
were diluted to a final concentration of 1 mg mL−1 SPIONs and 1 mg mL−1 RSSCpG (assuming
no loss) using deionized water. During synthesis of SPION-CpG, discoloration of sample tubes and
sedimentation upon dialysis membranes was observed, indicating that some of the material was lost.
However, it was not feasible to quantify the SPION loss on these surfaces. Similarly, the amount of
CpG lost during SPION-CpG synthesis is also difficult to quantify. Therefore as an approximation,
the concentrations reported in subsequent experiments assumed no loss of SPIONs and no loss of
CpG. At worst, when using this approximation we underestimated the immunostimulatory potential
and cell uptake efficiency of SPION-CpG.
4.5.2 Mass Spectroscopy
Using 3kD MWCO centrifugal spin filters (Amicon Ultra 0.5 mL, catalogue # UFC500324, EMD
Millipore), crude from the RSSCpG reduction reaction was washed with an ammonium acetateacetic
acid buffer (pH = 4.5) and deionized water for desalting. The sample was introduced by nanoelec-
trospray into a Thermo LTQ-FT operated in negative ion mode under manual control. Ions were
detected in the ICR cell at resolution 100,000 (at m/z 400).
4.5.3 NFkB Activity Assay
RAW-Blue mouse macrophage reporter cells (Invivogen) were cultured at 5000 cells per well (using
a 96-well plate; 6 repeat per group). Cells were treated with 10 µL of RSSCpG, SPION-CpG, or
water for 16 h. Both RSSCpG and SPION-CpG treated wells had the same final CpG concentration
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(0.1 mg mL−1). The level of secreted embryonic alkaline phosphatase (SEAP) was quantified by
incubating 10 µL of supernatant with 190 µL QuantiBlue substrate (InvivoGen) for 1 h and reading
absorption at 620 nm using DTX 880 Multimode Detector (Beckman Coulter). QuantiBlue substrate
was prepared by mixing one pouch of QUANTI-Blue in 100 mL of deionized water. The solution
was then filtered using a 0.2 µm membrane. QuantiBlue substrate was warmed at 37 ◦C prior to
use.
4.5.4 Physical Characterizations
Cytotoxicity assessment was performed using the LIVE/DEAD staining assay (Invitrogen). N9
microglia cells seeded at 9.6 x 104 cells per well in a glass bottom cell culture dish were grown to
80% confluence. For each viability assay, the cells were washed with PBS, treated with the SPION-
CpG conjugates and incubated for 12 h. After exposure to the different SPIONs, the cells were
rinsed with PBS and stained with calcein-AM and ethidium homodimer (EthD-1 or EthD-2). The
dyes were mixed together and appropriately diluted so that the effective working solution contains 2
µM of calcein-AM and 4 µM of ethidium homodimer which was then directly added to cells following
manufacturer’s protocol. After incubation with the dye, the cells were treated with fixative (either
glutaraldehyde for post-movement SEM samples or paraformaldehyde) and imaged.
Light microscopy images were obtained on several instruments: Nikon Eclipse TS100 microscope
equipped with Infinity2 camera (Nikon Instruments Inc., USA), Nikon Eclipse TE2000-U Inverted
Fluorescence microscope (Nikon Instruments Inc., USA), Zeiss Axio Observer Z1 Inverted micro-
scope with a Hamamatsu EMCCD C9100-13 Monochrome Camera, and a Zeiss LSM 710 confocal
laser-scanning microscope with a Plan-Apochromat 20x/0.8 objective (Carl Zeiss Microimaging,
Thornwood, NY). For confocal images, optical sections were collected at 1 µm spacing and shown as
a maximum intensity projection using Zen 2009 software (Carl Zeiss). For the Zeiss Axio Observer,
Zen 2012 blue software was used.
4.5.5 Inductively Coupled Plasma Mass Spectroscopy (ICP-MS) for Up-
take and Exocytosis
To quantify the total uptake of the SPION-CpG by the microglia N9 cells we performed ICP-MS
(4500 Series, Hewlett Packard) measurements. The cells were grown as described above and treated
with various concentrations of SPION-CpG (0, 0.01, 0.1, 0.3 and 0.5 mg mL−1) or Ferumoxytol (1.5
mg mL−1). After 12 h of exposure, the medium was aspirated, the cells were washed once with PBS
and were collected by treating with 0.2% trypsin-EDTA, followed by washing two times with PBS
and table-top centrifugation (1000 rpm, 5 min), acid digested overnight using 1 mL of 6770% BDH
Aristar Plus Nitric Acid, and analyzed using ICP-MS upon appropriate dilution. A standard curve
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was made using serial dilution of a 1 ppm solution of Iron standard solution (Spex CertiPrep). Iron
concentration was determined by ICPMS Analysis on a HP 4500 Series using a concentric nebulizer,
Scott type spray chamber, and a fixed quartz injector torch. A CX interface was used. Plasma
power was 1500 Watt. Helium was used as the collision gas (4 mL min−1). Data was analyzed
quantitatively in a spreadsheet program.
To evaluate exocytosis, N9 cells were plated at 6000 cells per well in a 96 well plate (18,000 cells
cm−2) and allowed to adhere for 24 h. The cells were then loaded at a 0.1 mg mL−1 concentration of
SPION-CpG for 2 h. After loading, the cells were washed twice with PBS and 150 µL fresh media was
added to each well. At t = 0 h, 8 h, and 24 h, media in the well was completely removed (supernatant
fraction) and both the amount of iron in both the supernatant and cell fractions was quantified via
ICP-MS. Each group was in triplicate and two independent experiments were performed.
ICP-MS for the exocytosis experiment was performed as follows: 200 µL BDH Aristar Plus Nitric
Acid (70%) was added to each sample tube (for the supernatant fraction) or well of a 96 well plate
(cell fraction) to dissolve the iron. Each tube or well was washed once with 200 µL of 70% Nitric
acid, the sample was then diluted to 3.4 mL with 3 mL of 2% nitric acid solution. Iron concentration
was determined by ICPMS Analysis on Agilent 7500 Series using a concentric nebulizer, Scott type
spray chamber, and a fixed quartz injector torch. A CX interface was used. Plasma power was
1500 Watt. Helium was used as the collision gas (4 mL min−1). A standard curve was made using
serial dilution of a 1 ppm solution of Iron standard solution (Spex CertiPrep). Data was analyzed
quantitatively in a spreadsheet program.
4.5.6 Dark-field microscopy imaging
Cells were grown to 80% confluence on a glass bottom cell culture dish for 2448 h. The cells were
loaded with 0.5 mg mL−1 SPION-CpG for 2 h. After loading, excess media was removed, and the
cells were washed extensively with PBS. The cover slips were carefully detached from the bottom of
the dishes using a sharp edge forcep and allowed to dry. A drop of non-drying immersion oil (Cargille
Laboratories, Cedar Glove, NJ) was put on the cover slip and the cover slip was mounted onto the
glass slide and was adhered using nail polish to prevent drying. Dark-field microscopy imaging was
performed using a CytoViva dark field microscope system equipped with CytoViva Hyperspectral
Imaging System 1.2.
4.5.7 Electron microscopy (SEM and TEM)
TEM imaging was performed on a FEI Tecnai 12 TEM equipped with a Gatan Ultrascan 2 K
CCD camera at an accelerating voltage of 120 kV. Cells treated with SPION-CpG conjugates (0.5
mg mL−1) as described earlier, were collected by treating with 0.2% trypsin-EDTA, followed by
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washing with PBS and table top centrifugation (2000 rpm, 5 min), fixed with 2% glutaraldehyde
in 0.1 M Cacodylate buffer (Na(CH3)2AsO23H2O), pH 7.2, at 4
◦C overnight. The following day
the cells were washed three times with 0.1 M Cacodylate buffer, post-fixed with 1% OsO4 in 0.1 M
Cacodylate buffer for 30 min and washed three times with 0.1 M Cacodylate buffer. The samples
were then dehydrated using 60%, 70%, 80%, and 95% ethanol and 100% absolute ethanol (twice),
propylene oxide (twice), and were left in propylene oxideEponate (1:1) overnight at room temperature
under sealed environment. The following day the vials were left open until the propylene oxide was
evaporated ( 23 h). The samples were infiltrated with 100% Eponate and polymerized at 64◦C for
48 h. Ultra-thin sections ( 70 nm thick) were cut using a Leica Ultra cut UCT ultra-microtome
equipped with a diamond knife, and the sections were picked up on 200 mesh copper EM grids. The
grids were stained with 2% uranyl acetate for 10 min followed by Reynold’s lead citrate staining for
a min prior to imaging.
SEM images of the magnetically-moved cells were obtained on an FEI Quanta 200 scanning elec-
tron microscope. Immediately after LIVE/DEAD staining, cells were fixed with 2% glutaraldehyde
in 0.1 M Cacodylate buffer (Na(CH3)2AsO23H2O), pH 7.2, at 4
◦C. The coverslip was then removed
from the glassbottom dish using Coverslip Removal Fluid (MatTek) following the manufacturer’s
protocol. The coverslip was then washed three times with 0.1 M Cacodylate buffer, pH 7.2, post-
fixed with 1% OsO4 in 0.1 M Cacodylate buffer for 30 min and washed three times with 0.1 M
Cacodylate buffer. The samples were then dehydrated through 60%, 70%, 80%, and 95% ethanol,
100% absolute ethanol (twice). The samples were dried in a critical-point dryer and then coated
with gold and palladium (Au : Pd 60/40 ratio) in a Cressington 308R coating system.
4.5.8 Magnetic-field Induced Qualitative Cell movement in vitro by Bright-
field Microscopy
For the magnetically induced cell movement experiments, microglia N9 cells were cultured as de-
scribed above. Cells were seeded at 9.3 x 105 cells per dish (9.7 x 104 cells cm−2), grown to 90%
confluence and treated with various concentrations (low: 0.1 mg mL−1, medium: 0.3 mg mL−1,
and high: 0.5 mg mL−1) of SPION-CpG conjugates. After 2 h of incubation, the loading medium
was aspirated, and the cells were washed extensively with PBS (carefully, until most of the free
SPION-CpG was gone), supplemented with fresh growth medium, and placed in the incubator with
a magnet placed underneath the dish separately. Further to show the controlled movement of cells,
three different shapes of magnets were used: square, circular, and rectangular. The movement of
cells towards the magnet was assessed at various times (0 h, 2 h, 4 h and 20 h) using microscopy.
In order to verify that increased iron concentration at the edge of the magnet was SPION-CpG-
loaded cells and not free particles in solution, a cell-free SPION-CpG-only control was included.
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These controls were stained for iron using Prussian blue staining as per manufacturer’s (Polyscience
Inc. Warrington, PA) instructions. Briefly, equal volumes of 4% potassium ferrocyanide and 4%
hydrochloric acid were mixed together to prepare the working solution. The standard staining re-
quired at least two changes of the working solution treatments for 10 min each, after which the cells
were rinsed three times with distilled water and stained using nuclear fast red for 3 min. Finally,
the cells were rinsed in running tap water for 1 min and imaged immediately.
4.5.9 Live Cell Imaging
In preparation for live cell imaging, the cell box was assembled and N9 cells plated on it. The
box was first sterilized by soaking in 0.6% NaOCl and rinsed thoroughly with autoclaved deionized
water in order to remove residual NaOCl (bleach). A large coverslip (48 mm x 65 mm no 1, Ted
Pella, catalogue #260365) was autoclaved and attached to the cell box using a non-cytotoxic silicone
based adhesive (Silbione Med Adhesive 4100 RTV, Factor II, catalogue #A-4100). The box-coverslip
assembly was then left at room temperature in a sterile environment (biosafety hood) for about 2
days in order to allow the adhesive to cure. After 2 days, an autoclaved polydimethylsiloxane
(PDMS) dam was placed on the coverslip in order to form a makeshift tissue culture dish. The
PDMS dam was created by first synthesizing a 0.5 cm thick rectangular slab of PDMS on a clean
glass surface (Sylgard 184 Silicone elastomer kit, Dow Corning, follow manufacturer’s protocol) and
then cutting an 9 cm2 rectangular hole in the PDMS. When this PDMS dam is set on the box-
coverslip assembly, it forms a water-tight seal with the coverslip. Once the dam is in place, N9 cells
(8.72 x 105 cells or 9.7 x 104 cells cm−2) were plated on the coverslip and allowed to adhere for 8
h in the incubator. The cells were then loaded at 0.1 mg mL−1 SPION-CpG for 2 h, following the
protocol for the previous cell movement experiment. After loading, the cells were washed with PBS,
the PDMS dam was removed and the box-coverslip assembly was inverted into a 100 mm petri dish
containing enough media to submerge the coverslip (1020 mL).
Live cell imaging was performed on a Zeiss Axio Observer Z1 Inverted microscope with the
Pecon/Zeiss Incubation System. Images were obtained using a 10x/0.3 NA EC-Plan Neofluar ob-
jective and a Hamamatsu EMCCD C9100-13 Monochrome Camera. The microscope and camera
were controlled using the Zen 2012 Blue Edition software. After connecting the cell box to the
microscope, pre-magnet images were taken for reference. A ceramic magnet was then placed on top
of the coverslip portion of the cell box above the region of the coverslip where cells are adhered. To
prevent the magnet from moving during the experiment, the magnet was secured to the coverslip
with tape. Using time-lapse imaging (1 bright-field image every 30 s), the motion of cells within
one field of view near the magnet was tracked over 20 h (the same time scale used for the other
movement experiment).
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